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ABSTRACT
Environmental agents are common causes of bladder cancer. Specifically, arsenic 
(As
3+
) and cadmium (Cd
2+
) are known carcinogens implicated in the development of 
bladder cancer. Previous studies from our laboratory have shown that As
3+
 and Cd
2+ 
can 
cause malignant transformation of normal immortalized bladder urothelial cells, which 
can form tumors when injected subcutaneous or intraperitoneal into nude mice. 
Microarray analysis of repeated metal transformation in parallel revealed that N-cadherin 
was the most upregulated gene in As
3+
 transformants, and a top induced gene in Cd
2+
-
transformed cells. The switch from E-cadherin to N-cadherin is a well-known indicator of 
the epithelial-to-mesenchymal transition occurring in bladder cancer. Further, N-cadherin 
upregulation is correlated with tumor stage, increased recurrence, and decreased survival 
in patients. While the factors mediating the decrease in E-cadherin expression are well-
established, little is known of the factors regulating the increase in N-cadherin 
expression. The goal of the present study was to determine how As
3+
 and Cd
2+
 regulate 
N-cadherin expression, whether this expression is maintained in heterotransplant models, 
and if N-cadherin is promoting the epithelial-to-mesenchymal transition in As
3+
- and 
Cd
2+
-transformed UROtsa cells in vitro. This work has demonstrated that N-cadherin is 
induced in As
3+
- and Cd
2+
-transformed UROtsa cell lines, and that the expression is 
maintained in intraperitoneal, but not subcutaneous, tumor xenografts. Further, tumor-
initiating cells derived from transformed UROtsa cells did not express N-cadherin. This 
xv 
 
suggests that tumor microenvironment and heterogeneity of cell populations are 
important factors for the use of animal models in cancer research. The As
3+
 and Cd
2+ 
UROtsa cell lines represent the initial phases of EMT in bladder cancer, and may 
demonstrate a unique EMT pathway specific to heavy metal carcinogens. Transcriptional 
regulation of N-cadherin, which is mostly unknown, may be elucidated by the 
investigation of the transcription factor Twist and epigenetic regulation, particularly 
histone acetylation. 
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CHAPTER I 
INTRODUCTION 
Environmental Background in Bladder Cancer 
The first link between environmental agents and bladder cancer was discovered 
by Ludwig Rehn in1895, in which he found an increased incidence of bladder cancer in 
workers using aniline at a dye manufacturer in Frankfurt, Germany (Dietrich & Dietrich, 
2001; Rehn, 1895). The findings of Rehn initiated the study of occupational bladder 
carcinogens and spurred the development of occupational toxicology. Later in 1937, 2-
naphthylamine, an aromatic amine, was found to be the bladder cancer-causing agent 
(Hueper, Wiley, & Wolfe, 1938). By the 1950’s, subsequent studies of industrial workers 
lead to the discovery of multiple other aromatic amines which cause bladder cancer. 
Exposure to carcinogenic aromatic amines was found in the rubber, textile, and chemical 
industries (Johansson & Cohen, 1997). 
Slowly, regulations were instituted which have limited occupational exposure to 
these bladder carcinogens. With this reduction, cigarette smoking is now the main cause 
of bladder cancer in the United States (Freedman, Silverman, Hollenbeck, Schatzkin, & 
Abnet, 2011). There is an approximately 3 times higher risk for bladder cancer in 
smokers versus non-smokers (Zeegers, Tan, Dorant, & Van Den Brandt, 2000). While the 
precise mechanism is unclear, aromatic amines, unsaturated aldehydes, and cadmium in 
cigarettes are known carcinogens (Johansson & Cohen, 1997; Vineis & Pirastu, 1997). 
Smokers are exposed to 1.7 µg cadmium per cigarette, and have double the body burden 
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of cadmium compared to non-smokers (ATSDR, 2012). Cigarettes also contain arsenic at 
levels up to 1.4 µg per cigarette (C. Smith, Livingston, & Doolittle, 1997). 
Bladder cancer due to arsenic exposure was initially discovered in Taiwan, where 
residents drank water from artesian wells containing high amounts of the metal. Arsenic-
induced bladder cancer has been confirmed by a number of studies since then. 
Evidence of bladder carcinogenesis due to cadmium exposure is seen in Belgium, 
where increasing levels of blood cadmium were correlated with cancer risk (Kellen, 
Zeegers, Hond, & Buntinx, 2007). However, the evidence for cadmium-induced bladder 
cancer is less than that of arsenic.  
Chronic infection with the parasite Schistosoma haematobium is also known to 
cause bladder cancer, predominantly squamous cell carcinoma (Mostafa, Sheweita, & 
O’Connor, 1999). Chronic infections in addition to that of Schistosoma haematobium 
may also promote bladder cancer, though direct links have yet to be proven (Abol-Enein, 
2008). 
Arsenic Causes Bladder Cancer 
The general public is exposed to arsenic primarily by the oral route through food and 
drinking water (ATSDR, 2007). Oral ingestion of inorganic arsenic is known to cause 
skin, kidney, liver, lung, and prostate cancer in addition to that of bladder. Average 
dietary consumption of inorganic arsenic in the United States is 10.22 µg/day (MacIntosh 
et al., 1997), while exposure through drinking water is about 5 µg/day (ATSDR, 2007). 
The current limit of arsenic in drinking water is 10 ppb (EPA, 2001). Arsenic can leach 
from the soil into ground and surface water. Releases into the environment are mainly 
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from anthropogenic sources including nonferrous metal mining and smelting, pesticide 
use, coal and wood combustion, and waste combustion (ATSDR, 2007).  
Evidence of Arsenic Carcinogenicity 
Numerous epidemiological studies have proven the link between arsenic and bladder 
cancer. The discovery of arsenic-induced bladder cancer in Taiwan was initiated by the 
high incidence of blackfoot disease, a peripheral artery disease caused by arsenic 
exposure (Tseng, 1977). Upon investigation of these blackfoot-endemic regions, it was 
found that residents of this area also had high rates of bladder cancer (C. J. Chen, 
Chuang, Lin, & Wu, 1985). High exposure to arsenic in drinking water was later 
confirmed as the cause of bladder cancer in this region. 
Following initial reports of increased bladder cancer in Taiwan (C J Chen, Chen, Wu, 
& Kuo, 1992; C J Chen, Chuang, You, Lin, & Wu, 1986; C. J. Chen et al., 1985; C. J. 
Chen & Wang, 1990; Chiou et al., 1995; L. Wang et al., 2012), evidence arose of bladder 
cancer due to arsenic in drinking water in Argentina (Hopenhayn-Rich et al., 1996) and 
Chile (A. H. Smith, Goycolea, Haque, & Biggs, 1998). More recent studies have shown 
links between arsenic in drinking water and bladder cancer in Tunisia (Feki-Tounsi et al., 
2013b) and Pakistan (Wadhwa, Kazi, Afridi, Tüzen, & Citak, 2013). Studies of bladder 
cancer in Chile show that the effects of arsenic exposure have a long latency period, as 
increased bladder cancer mortality rates did not appear until 10 years following exposure 
to arsenic-contaminated drinking water (Marshall et al., 2007). Even 40 years later, 
bladder cancer odds ratios were elevated compared to the general population (Steinmaus 
et al., 2013). In Taiwan, studies report reduced bladder cancer incidence and mortality 
only after twenty years of exposure cessation through installation of tap water systems 
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(C.-C. Su, Lu, Tsai, & Lian, 2011; C.-Y. Yang, Chiu, Chang, Ho, & Wu, 2005), though 
rates remained elevated compared to the general population.  
Epidemiological studies have been performed in the United States to determine if 
bladder cancer rates in Taiwan and other countries may be used to extrapolate risk at 
lower concentrations typically seen in the United States, as well as in populations of 
differing ethnicity. Previous studies showed increased bladder cancer risk at exposures 
over 300 mg/L (C. Chen et al., 2009; Chiou et al., 1995) Studies in Utah, Michigan, and 
Idaho with arsenic concentrations of 0-166 µg/L in drinking water found no change in 
bladder cancer risk, incidence, or mortality rates (Han, Weissfeld, Davis, & Talbott, 
2009; Lewis, Southwick, Ouellet-Hellstrom, Rench, & Calderon, 1999; Meliker et al., 
2010; Meliker, Wahl, Cameron, & Nriagu, 2007). In 2004, a nationwide study found no 
correlation between arsenic exposures of 3-60 µg/L and bladder cancer mortality rates 
(Lamm et al., 2004). A meta-analysis of 9 studies for bladder cancer risk also found no 
significant difference, though it suggested that the influence of cigarette smoking should 
be evaluated at these lower exposure levels (J. S. Tsuji, Alexander, Perez, & Mink, 
2014). Finally, an epidemiological study in Taiwan that was re-evaluated to exclude high 
arsenic exposures found that bladder cancer risk does not increase until 100-200 µg/L in 
drinking water (Lamm et al., 2014). 
Animal models of arsenic-induced bladder cancer have been difficult to replicate. 
Past studies with inorganic exposure alone have not found increased incidence of bladder 
tumors, except in whole-life exposure. Mice exposed to inorganic arsenic prior to 
breeding, during pregnancy, lactation, and after weaning through adulthood show 
increased levels of urinary hyperplasia (Tokar, Diwan, Ward, Delker, & Waalkes, 2011). 
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There are mixed results with organic arsenic carcinogenicity models. Exposure to 
dimethylarsenic acid for 2 years at 12.5, 50, and 200 mg/L in drinking water causes a 
significant increase in bladder tumors and urothelial hyperplasia (Wei et al., 2002; Wei, 
Wanibuchi, Yamamoto, Li, & Fukushima, 1999) and dietary exposure to 100 mg/L DMA 
causes urothelial cell papilloma and carcinoma in rats (Arnold, Eldan, Nyska, van 
Gemert, & Cohen, 2006). However, DMA in the diet does not cause cancer in mice at 
exposures up to 500 ppm (Arnold et al., 2006).  
There are cases in which arsenic acts as a co-carcinogen in animal models. 
Gestational exposure to 85 mg/L inorganic arsenic in mice followed by postnatal 
tamoxifen treatment increases formation of urinary bladder transitional cell tumors and 
bladder hyperplasia compared to either treatment individually (Waalkes, Liu, Ward, & 
Diwan, 2006). Increased urinary bladder proliferative lesions are also seen for 
transplacental inorganic arsenic exposure followed by postnatal diethylstilbestrol 
treatment (Waalkes et al., 2006). DMA treatment enhances tumor induction in 
diethylnitrosamine, N-butyl-N-(4-hydroxybutyl)nitrosamine, N-methyl-N-nitrosourea, 
dihydroxy-di-N-propylnitrosamine, and N-N'-dimethylhydrazine-treated rats (S. 
Yamamoto et al., 1995). 
Potential Mechanisms of Cancer Induction by Arsenic 
The mechanism by which arsenic causes bladder cancer has yet to be elucidated. The 
general theory is that inorganic arsenic undergoes metabolism to reactive metabolites 
which cause cytotoxicity. In response, the urothelium undergoes regenerative 
proliferation, leading to development of tumors. (Arnold et al., 2014; Cohen, Arnold, 
Beck, Lewis, & Eldan, 2013). Inorganic arsenic undergoes a series of reductions and 
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methylations leading to the formation of reactive metabolites including oxygenated 
compounds of trivalent and pentavalent arsenic, as well as thiolated pentavalent arsenic 
compounds. Inorganic pentavalent arsenate is converted to trivalent arsenite (AsIII) 
mainly in the blood and liver by arsenate reductase, followed by transport into cells 
(Figure 1.1). Inorganic arsenic may be transported by a number of proteins including 
aquaporin (Z. Liu et al., 2002), phosphate transporters (Rosen, 2002) and glucose 
transporters (Drobná et al., 2010). Inside the cell, arsenic methyltransferase converts 
trivalent arsenite to pentavalent monomethylarsonic acid (MMAV). Monomethylarsonic 
acid is then reduced to trivalent monomethylarsenous acid (MMAIII) by 
monomethylarsonic acid reductase and oxidatively methylated by monomethylamine 
methyltransferase to form dimethylarsenic acid (DMAV) (Cohen, Arnold, Eldan, Lewis, 
& Beck, 2006). The liver is the main site of methylation and reduction, though arsenite 
may be metabolized in other tissues (Vahter, 2002). Monomethylarsenic acid and 
DMA(V) are the predominant metabolites found in the urine following inorganic arsenic 
exposure (Vahter, 2002). In mice exposed to arsenate, both DMA(V)  and inorganic 
arsenic may be found in the urine, though DMA(V) is the major metabolite (Hughes et 
al., 2003; Kenyon et al., 2008). However, humans generate more MMA(V) than other 
animals (Hernández-Zavala et al., 2008). Rats metabolize DMA(V) to trimethylarsenic 
oxide, while humans do not, an important factor to consider when using rats as a model 
for arsenic metabolism and carcinogenesis (Cohen et al., 2006).  
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Figure 1.1 Metabolism of arsenate. Adapted from (Y. Chen et al., 2003). 
As(V): Arsenate, As(III): Arsenite, MMA(V): Monomethylarsonic acid, MMA(III): 
Monomethylarsenous acid, DMA(V): Dimethylarsenic acid 
 
Trivalent and pentavalent arsenicals, both organic and inorganic, are cytotoxic, 
though the species differ in potency, and cytotoxicity dependent upon its concentration 
and potential to react with sulfhydryl groups (Cohen et al., 2006; Yager et al., 2013). 
Trivalent arsenicals are considered more toxic due to their greater transport efficiency 
into the cell and enhanced binding affinity to sulfhydryl groups (Cohen et al., 2006). 
Dimethylarsonous acid, DMA(V), and As(III) are the most toxic to bladder cells (Cohen 
et al., 2002; Styblo et al., 2000)  
The mechanisms which mediate arsenic cytotoxicity can include genotoxicity, 
oxidative stress, and dysregulation of cell signaling pathways. Trivalent arsenicals bind 
selectively to sulfhydryl-containing proteins including metallothionein, rat hemoglobin, 
and zinc finger proteins (Demicheli et al., 2011; G. Jiang, Gong, Li, Cullen, & Le, 2003; 
Kitchin & Wallace, 2008; Yan, Wang, Weinfeld, Cullen, & Le, 2009; X. Zhou et al., 
2011). The effect of this interaction on cytotoxic mechanisms therefore is dependent 
upon cell type and arsenic species (Cohen et al., 2013). 
While arsenic is not mutagenic, it causes genotoxicity through inhibition of DNA 
repair systems or the generation of reactive oxygen species (ROS) that are damaging to 
DNA (Klein, Leszczynska, Hickey, & Rossman, 2007; Nesnow et al., 2002). Methylated 
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arsenic metabolites interact with zinc finger proteins involved in DNA repair and damage 
signaling, inhibiting base excision repair and nucleotide excision repair (Hartwig et al., 
2002). Further, arsenic-induced bladder cancer risk is increased in individuals with a 
variant of XRCC3, a double-strand break repair gene (Andrew et al., 2009). DNA 
damage induced by MMA(III) and DMA(III) is prevented by treatment with ROS 
inhibitors Tiron, melatonin, and the vitamin E analog Trolox (Nesnow et al., 2002). 
Oxidative stress due to arsenic exposure is damaging to lipids and proteins, in 
addition to DNA. Trivalent arsenicals, particularly DMA(III), cause lipid peroxidation 
and the protein oxidation in vitro (Shi, Shi, & Liu, 2004; T.-C. Wang, Jan, Wang, & 
Gurr, 2007). Sodium arsenite and MMA(III) induce ROS in the immortalized human 
urothelial cell line UROtsa which is reverted by catalase or superoxide dismutase. 
Oxidative DNA damage is observed, as well as induction of Hsp70 and metallothionein, 
a protein which protects the cell against metal toxicity and oxidative stress (Eblin et al., 
2006; Michael R Rossi et al., 2002). Glutathione is a major antioxidant of the cell 
(Forman, Zhang, & Rinna, 2009), and is the electron donor for the reduction of arsenate 
to arsenite (Scott, Hatlelid, MacKenzie, & Carter, 1993). A decrease in glutathione and 
an increase of glutathione disulfide, the oxidized peptide created during ROS 
detoxification, is an indicator of chronic oxidative stress (Lu, 2009). Glutathione is a 
tripeptide containing a cysteine residue available for arsenite binding (Scott et al., 1993). 
In mice and humans exposed to arsenic-containing water for prolonged periods, liver 
glutathione is decreased, accompanied by an induction in glutathione disulfide (Hall et 
al., 2013; Santra, Maiti, Chowdhury, & Mazumder, 2000). Low arsenite exposure in 
UROtsa cells stimulates an accumulation of ubiquitin-conjugated protein that is increased 
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upon reduction of cellular glutathione, suggesting that glutathione may prevent disruption 
of the ubiquitin-proteasome pathway caused by arsenic (Bredfeldt, Kopplin, & Gandolfi, 
2004). Thioredoxin, an electron donor for the reduction of MMA(V) to MMA(III), is also 
an important cell antioxidant (Kitchin & Wallace, 2008). Thioredoxin activity is 
decreased following As(III) and MMA(V) exposure in hepatocytes (S. Lin et al., 2001), 
which may mediate arsenic-induced apoptosis (Arnér & Holmgren, 2000; Shi et al., 
2004).  
Several epigenetic modifications are altered in arsenic-induced carcinogenesis, 
including DNA methylation and histone acetylation, to enhance expression of tumor-
promoting genes. It is believed that methylation during arsenic biotransformation by 
arsenic methyltransferase depletes availability of the methyl donor S-adenosyl 
methionine (SAM), reducing DNA methylation activity to cause a global hypomethylated 
state (Bustaffa, Stoccoro, Bianchi, & Migliore, 2014). However, while hypomethylation 
is a prominent global characteristic of arsenic transformation, many cell types and 
specific genes do not demonstrate hypomethylation, including UROtsa cells transformed 
with MMA(V). This study found that alterations in DNA methylation occurr non-
randomly at hundreds of gene promoters to alter gene expression. Further, the DNA 
methylation changes are permanent, as removal of arsenic does not alter DNA 
methylation levels, gene expression, or malignant phenotype (Jensen, Novak, Wnek, 
Gandolfi, & Futscher, 2009).  
Urothelial cancers from arsenic-contaminated areas show gene-specific 
hypermethylation of death-associated protein kinase (DAPK), a member of the apoptosis 
pathway downstream of interferon-γ, TNF-α, and Fas signaling. Hypermethylation of the 
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DAPK promoter is correlated with tumor invasiveness, grade, and recurrence. 
Hypermethylation of the DAPK promoter is associated with decreased expression (W. T. 
Chen, Hung, Kang, Huang, & Chai, 2007). In SV-HUC-1 cells exposed to sodium 
arsenite, promoter hypermethylation of the tumor suppressor RECK leads to decreased 
expression of the gene, a tumor invasion and angiogenesis suppressor (Y. Huang, Hung, 
Chen, Yu, & Chai, 2011). Urothelial cancers from blackfoot disease-endemic areas also 
show decreased RECK protein levels compared to cancers from non-endemic regions (Y. 
C. Huang et al., 2011). Additionally, urothelial carcinomas from a blackfoot disease area 
show elevated expression of cyclin D1 that is confirmed in arsenite-treated SV-HUC-1 
cells. Further, cyclin D1 expression is dependent upon DNA methylation state (Y. C. 
Huang et al., 2011). Hypermethylation of the CTBP1 promoter has been observed in 
HUC-1 cells exposed to transforming levels of sodium arsenite, accompanied by 
increased expression of the gene which is involved in regulation of epithelial phenotype 
(Grooteclaes & Frisch, 2000; Michailidi et al., 2015; Peinado, Olmeda, & Cano, 2007). 
Conversely, arsenite causes hypermethylation of the HER2 and NFĸB2 promoters, 
increasing gene expression (Michailidi et al., 2015). In another study, chronic sodium 
arsenite exposure to immortalized human urothelial cells causes hypomethylation and 
overexpression of lipocalin-2, an oncogene that promotes metastasis through the 
LCN2/MMP9 complex and enhancement of the epithelial-to-mesenchymal transition (H. 
H. Wang et al., 2014).  
Assessment of the histone acetylation state of 13,000 promoters in arsenite-
transformed UROtsa cells and normal UROtsa cells exposed to transforming levels of 
MMA(III) reveals changes in histone H3 acetylation, which enhances DNA 
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hypermethylation at these regions to alter the expression state of the associated gene 
(Jensen, Novak, Eblin, Gandolfi, & Futscher, 2008).  
Alterations in histone acetylation are also believed to promote carcinogenesis in 
bladder (Bustaffa et al., 2014). Quantitative mass spectrometric analysis of histone 
epigenetic state following arsenite or MMA(III) exposure to UROtsa cells discovered a 
global decrease in acetylation at several H3 and H4 lysine residues (Chu et al., 2011). 
MYST1, a histone 4 lysine 16 acetyltransferase plays a role in urothelial resistance to 
arsenic cytotoxicity. UROtsa cells lacking the MYST1 gene show increased sensitivity to 
arsenite and MMA(III), along with dose- and time-dependent decreases in global H4K16 
acetylation (Jo et al., 2009). In another study, low level MMA(III) exposure increases 
expression and activity of histone deacetylases, leading to reduced global histone 
acetylation in UROtsa cells (Ge et al., 2013). 
In a review of genomic dose-response information in models of arsenic 
carcinogenesis, common pathways altered by chronic low exposure include oxidative 
stress, proteotoxicity, inflammation, proliferative signaling, DNA repair, cell cycle G2/M 
checkpoint control, and induction of apoptosis (Xie et al., 2010). The arsenic-transformed 
UROtsa cells demonstrate permanent induction of pathways involved in mismatch repair, 
amino acid metabolism, glycolysis/gluconeogenesis and alkaloid biosynthesis and 
repression of apoptosis and endocytosis pathways (unpublished data). Global gene 
expression analysis has also been performed on 1T1 bladder cells exposed to As(III), 
MMA(III), and DMA(III) for 24 hrs. Among all arsenicals, the NRF2-mediated oxidative 
stress response, cholesterol biosynthesis, and interleukin-10 signaling pathways are 
altered (Dodmane et al., 2013). Indeed, NRF2-repressed UROtsa cells demonstrate 
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increased sensitivity to sodium arsenite and MMA(III), while NRF2 overexpression 
promotes a tolerance to arsenic cytotoxicity (X.-J. Wang et al., 2007). In another study of 
As(III) and MMA(III) treated cells, the p53 signaling pathway is deregulated in both 
treatments, while changes in cell cycle regulation and DNA damage response are unique 
to As(III) exposure (Dodmane et al., 2013). UROtsa cells exposed to 50 nM MMA(III) 
are malignantly transformed after 3 months. While subtle changes in gene expression 
occurr over the first 2 months, the same pathways are substantially altered at 3 months. 
These include oxidative stress, cell proliferation, anti-apoptosis, MAPK and 
inflammation pathways (Medeiros et al., 2012).  
Proteomic analysis of primary and immortalized uroepithelial cells treated with 
arsenite trioxide for 3 weeks shows alterations in proteins involved with nucleotide 
binding, lipid metabolism, protein folding, biosynthesis, transcription, DNA repair, cell 
cycle control, and signal transduction (S. Chen et al., 2010). Genomic analysis of mouse 
urine exposed to arsenate in drinking water for up to 12 weeks discovered enhanced 
epithelial-to-mesenchymal transition, inflammation, and proliferation pathways, while in 
a study of rat urothelium after exposure to DMA(III) for 28 days, changes were seen in 
genes for apoptosis, cell cycle regulation, oxidative stress response, and cancer control 
processes (Clewell et al., 2011; Sen, Wang, Hester, Robertson, & Wolf, 2005).  
Cadmium Causes Bladder Cancer 
Cadmium was demonstrated to have negative consequences for human health in 
1955, when outbreaks in Japan of Itai-Itai disease, translated as “it hurts-it hurts”, were 
linked to cadmium exposure. Releases of cadmium effluent from a nearby zinc mine 
contaminated rice paddies, which provided the main source of food for residents in the 
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area. Toxicity is characterized by renal injury due to tubular and glomerular dysfunction 
and bone injury consisting of osteomalacia and osteoporosis. Initial femoral pain spreads 
throughout the body, ultimately causing the patient to become bed-ridden (Inaba et al., 
2005). 
Exposure to cadmium in humans is mainly through diet and cigarette smoking (NTP, 
2011). The largest contribution to dietary cadmium is leafy vegetables including lettuce 
and spinach, potatoes and grain, peanuts, soybeans, and sunflower seeds (ATSDR, 2012; 
FDA, 2008). Liver and shellfish also contain higher levels of cadmium (ATSDR, 2012; 
Satarug & Moore, 2004). Occupational exposure to cadmium may occur in zinc and iron 
ore smelting, welding cadmium-coated steel, working with solders containing cadmium, 
and handling or producing cadmium powders (NTP, 2011). The estimated cadmium 
intake is 0.35 µg/kg/day in males and 0.30 µg/kg/day in females (Choudhury et al., 
2001). Cadmium is found in the Earth’s crust and is distributed in dust, volcanic 
emissions, and forest fires along with other natural phenomena (ATSDR, 2012). 
However, anthropogenic production is the main source of cadmium in the environment. 
Zinc, copper, and lead smelting, coal and oil-fired broilers, and industrial waste 
incinerators release cadmium into the environment. Application of phosphate fertilizers 
and waste leaching from landfills also releases cadmium into the soil and water (EPA, 
1985).  
Evidence of Cadmium Carcinogenicity 
Cadmium is classified as a carcinogen (IARC, 1993), though the evidence for bladder 
cancer induction by cadmium is less than that of arsenic. In a study of bladder cancer 
cases in Belgium, increasing levels of blood cadmium are correlated with bladder cancer 
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risk (Kellen et al., 2007). However, a study of cancer incidence in northeastern Belgium 
and southeastern Netherlands found no correlation between long-term emission of 
cadmium by zinc smelters and bladder cancer incidence (Verhoeven et al., 2011). A study 
of Tunisian men also found that blood cadmium levels are significantly higher in cases of 
bladder cancer and that cadmium levels are correlated with smoking and age (Feki-
Tounsi et al., 2013a). Urinary metallothionein-bound cadmium is significantly elevated in 
transitional cell carcinoma patients as measured by inductively coupled plasma mass 
spectrometry (Wolf, Strenziok, & Kyriakopoulos, 2009). In addition, a study based in 
Montreal, Quebec, Canada implicates occupational exposure to cadmium compounds to 
bladder cancer risk (Siemiatycki, Dewar, Louise, & Gérin, 1997). One difficulty in 
epidemiological studies of cadmium-induced carcinogenesis is the confounding factor of 
cigarette smoking. In fact, no studies have found a significant association between 
cadmium and bladder cancer in non-smokers (Feki-Tounsi & Hamza-Chaffai, 2014). 
Future experiments with larger sample size and non-smoking populations will help to 
determine the role of cadmium in bladder cancer. 
While animal studies confirm cadmium as a carcinogen, no cadmium exposure 
studies have demonstrated the development of bladder cancer specifically in animals. 
However, in vitro exposure to cadmium chloride malignantly transforms urothelial cells 
as indicated by anchorage independent cell growth and tumor formation in nude mice 
(Sens et al., 2004). 
Potential Mechanisms of Cancer Induction by Cadmium 
The manner by which cadmium causes bladder cancer, and all cancers in general, 
remains unknown. As with arsenic-induced bladder cancer, the likely mechanism of 
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cancer induction by cadmium is that of initial cytotoxicity followed by regenerative 
proliferation and the development of tumors. The processes involved in each step, 
however, are likely unique due to the inherent differences in cadmium and arsenic. 
Changes observed during cadmium carcinogenesis include aberrant gene expression, 
DNA damage repair inhibition, impairment of apoptosis, and oxidative stress (Feki-
Tounsi & Hamza-Chaffai, 2014).  
Following absorption at the small intestine, ingested cadmium accumulates 
predominantly in the kidney and to a lesser extent in liver (Satarug, Baker, Reilly, Moore, 
& Williams, 2002; Sumino, Hayakawa, Shibata, & Kitamura, 1975), and has a biological 
half-life of at least 15-20 years (ATSDR, 2012; Jin, Lu, & Nordberg, 1998). 
Metallothionein, a cysteine-rich antioxidant protein, plays an important role in cadmium 
accumulation, as cadmium has the ability to bind protein thiol groups (Carballo, 
Castineiras, Dominguez-Martin, Garcia-Santos, & Niclos-Gutierrez, 2013). 
Metallothionein readily binds cadmium in the liver, preventing its excretion. In 
metallothionein-null mice, absorption and distribution of the metal is unaffected, 
however, elimination through the bile is inhibited, causing accumulation of cadmium-
bound metallothionein in the body (Klaassen, Liu, & Choudhuri, 1999). Though 
metallothionein accumulates cadmium in the kidney, it is protective against 
nephrotoxicity. In metallothionein-null mice, renal toxicity iss enhanced compared to 
controls (J. Liu, Liu, Habeebu, & Klaassen, 1998). Metallothionein expression is also 
induced upon cadmium exposure in the kidney and bladder (Chung, Nartey, & Cherian, 
1986; Sens et al., 2003)  
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Mechanisms of cadmium transport have not been fully elucidated. Cadmium has no 
known biological function and utilizes transporters for zinc, iron, and calcium.  Known 
cadmium transporters include divalent metal transporter 1 (SLC11A2) (Park, Cherrington, 
& Klaassen, 2002), ZIP8 (SLC39A8) (Dalton et al., 2005), and ZIP14 (SLC39A14) 
(Girijashanker et al., 2008). Recent studies have implicated megalin as a transporter of 
cadmium-bound metallothionein (Wolff, Abouhamed, Verroust, & Thévenod, 2006). 
Cadmium transport and accumulation is enhanced upon deficiency of the dietary metals 
zinc, iron, and calcium (Ueda et al., 1987; Vesey, 2010), such that nutritional state must 
be considered in studies of cadmium toxicity and transport. 
Due to the lack of animal models, mechanisms of cadmium-induced bladder cancer 
have been investigated in vitro. Inhibition of apoptosis is one manner in which cadmium 
causes carcinogenesis. In normal cells, cadmium often induces apoptosis initially, 
followed by resistance upon malignant transformation. Cadmium-transformed prostate 
epithelial cells exhibit enhanced resistance to apoptosis induced by cadmium, 
accompanied by down-regulation of several caspase family members and overexpression 
of anti-apoptotic genes (W. Achanzar, Webber, & Waalkes, 2002). Cadmium exposure to 
the nontransformed prostate epithelial cell line RWPE-1 induces apoptosis in 65% of 
cells; however, the surviving 35% have elevated levels of metallothionein (W. E. 
Achanzar, Achanzar, Lewis, Webber, & Waalkes, 2000). This suggests that 
metallothionein may promote the survival of cadmium-exposed cells. Similarly, alveolar 
epithelial cells subjected to repeated in vitro exposure to cadmium demonstrate increased 
resistance to apoptosis caused by the oxidant hydrogen peroxide, along with elevated 
expression of Metallothionein 1 and 2 (Eneman et al., 2000). Indeed, similar results are 
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observed in transformation of UROtsa cells by arsenite and cadmium. The UROtsa cell 
line exposed to toxic levels of sodium arsenite and cadmium chloride experience both 
apoptosis and necrosis. Meanwhile, UROtsa cells malignantly transformed with arsenite 
and cadmium display increased resistance to arsenite- and cadmium-induced toxicity, and 
are more likely to undergo necrosis, suggesting that apoptosis inhibition may promote 
heavy metal carcinogenesis. In both parent UROtsa and Cd
2+
-transformed cells, cadmium 
exposure induce metallothionein. However, there is no difference in the level of induction 
between the normal and transformed cells, indicating that metallothionein does not play a 
role in arsenic or cadmium transformation (Somji, Zhou, Garrett, Sens, & Sens, 2006).  
Cadmium may induce cytotoxicity and carcinogenesis by interfering with cysteine-
containing proteins such as the tumor suppressor p53. In human breast cancer MCF-7 
cells, p53 induction by DNA-damaging agents is inhibited by cadmium (Méplan, Mann, 
& Hainaut, 1999). While initial exposure to cadmium induces p53 expression in human 
prostate epithelial cells, continued exposure reduces levels to those below baseline (W. E. 
Achanzar et al., 2000). 
Bladder-specific mechanisms of cadmium carcinogenesis has been investigated by 
this lab in regard to aberrant gene expression. Transformation of the UROtsa cell line by 
chronic cadmium exposure results in permanent induction of genes associated with 
mismatch and nucleotide excision repair, DNA replication, amino acid metabolism, 
glycolysis/gluconeogenesis, and sphingolipid metabolism. Repressed pathways included 
apoptosis, the Jak-STAT signaling pathway, and Wnt signaling (unpublished data). 
Oxidative stress has not been studied in cadmium-induced bladder cancer 
specifically, but are common traits of cadmium carcinogenicity in other tissues. 
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Cadmium exposure induces numerous radical species, including hydrogen peroxide, 
superoxide anions, and hydroxyl anions (Bertin & Averbeck, 2006). Oxidative stress due 
to cadmium has been observed both in vitro and in animal studies (Joseph et al., 2001; 
Koizumi, Shirakura, Kumagai, Tatsumoto, & Suzuki, 1996; Nigam, Shukla, & Agarwal, 
1999; Shih et al., 2004). In a study of the general population, urinary cadmium levels are 
correlated to increased serum γ-glutamyltransferase and decreased vitamin C, 
carotenoids, and vitamin E (Lee, Lim, Song, Boo, & Jacobs, 2006). However, cadmium 
is not a Fenton metal, indicating that oxidative stress is generated indirectly by cadmium 
(Bertin & Averbeck, 2006). 
 Cadmium may induce oxidative stress indirectly by reducing the levels or activity of 
antioxidant enzymes, increasing the cell's vulnerability to ROS (Waisberg, Joseph, Hale, 
& Beyersmann, 2003). Second, cadmium may displace iron from ferritin and apoferritin, 
making iron available for ROS-producing Fenton reactions (Casalino, Sblano, & 
Landriscina, 1997; Price & Joshi, 1983). Cadmium may also induce oxidative stress by 
interfering with oxidative metabolism in mitochondria (Bertin & Averbeck, 2006; Nigam 
et al., 1999). Cadmium-mediated oxidative stress leads to mutations and damage to DNA, 
as well as lipids in several organs and cell types (Bertin & Averbeck, 2006). 8-
hydroxydeoxyguanosine formation, indicative of premutagenic lesions due to oxidative 
stress, and DNA strand breaks are caused by cadmium exposure in HeLa and 
lymphoblastoid cells (Dally & Hartwig, 1997; Mikhailova, Littlefield, Hass, Poirier, & 
Chou, 1997). In addition to their damaging effects, ROS may act as signaling molecules 
(Bertin & Averbeck, 2006). Reactive oxygen species generated by cadmium activates 
extracellular signal-regulated kinases (ERK) and AKT to induce the pro-angiogenic 
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molecule hypoxia-inducible factor-1 in human bronchial epithelial cells (Jing et al., 
2012). In BALB/c-3T3 cells transformed with cadmium chloride, ROS mediates the 
upregulation of proto-oncogenes c-fos, c-jun, and c-myc (Joseph et al., 2001). The 
relative importance of ROS in cadmium carcinogenesis is still unclear. In a study of rat 
liver epithelial cells transformed by chronic cadmium exposure, initial induction of ROS 
is abolished well before malignant transformation (Qu et al., 2005). 
Cadmium may mediate carcinogenesis through the inhibition of various DNA damage 
repair mechanisms, including base excision repair, nucleotide excision repair, and 
mismatch repair (Giaginis, Gatzidou, & Theocharis, 2006), though alterations in these 
processes have not been studied in bladder cancer specifically. Cadmium has been found 
to inhibit numerous steps of base excision repair. Cadmium reduces the activity of 8-
oxoG glycosylase, an enzyme involved in the initiation of repair (Potts, Bespalov, 
Wallace, Melamede, & Hart, 2001). It also suppresses the activity of 8-oxo-2'-
deoxyguanosine 5-triphosphate pyrophosphohydrolase, an enzyme which prevents 
incorporation of mutagenic 8-oxo-dGTP (Bialkowski, Bialkowska, & Kasprzak, 1999). 
Ape-1 endonuclease and exonuclease action is inhibited by cadmium in vitro, as well as 
DNA polymerase β (Popenoe & Schmaeler, 1979) and DNA ligase 1 (McNeill, 
Narayana, Wong, & Wilson, 2004; S. W. Yang, Becker, & Chan, 1996).  
Studies on the effect of cadmium exposure on nucleotide excision repair reveal that 
the metal inhibits initial phases of this process (Giaginis et al., 2006). Transcription factor 
IIIA, an enzyme important in the initiation of nucleotide excision repair, is impaired in its 
ability to bind DNA by cadmium. It is thought that cadmium binds to cysteines within the 
zinc finger protein to inhibit DNA binding (Hanas & Gunn, 1996). Cadmium reduces the 
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DNA binding ability of XPA, another initiator of nucleotide excision repair, likely due to 
sensitivity of the zinc finger protein to cadmium (Asmuss, Mullenders, Eker, & Hartwig, 
2000).  
There is evidence that cadmium suppresses initial phases of mismatch repair by 
inhibiting MSH2-MSH6-dependent activity, attenuating the complex’s DNA binding 
affinity and reducing its ability to distinguish mismatched duplexes (Clark & Kunkel, 
2004). Cadmium also inhibits DNA mismatch-repair-mediated cell cycle arrest following 
alkylation damage (Lützen, Liberti, & Rasmussen, 2004). However, the mechanisms of 
protein inhibition in mismatch repair does not appear to be due to the targeting of zinc 
finger motifs (Giaginis et al., 2006). 
Cadmium- and Arsenic-transformed UROtsa Cells 
Immortalized human bladder cancer-derived cell lines are widely available and well 
characterized, however, they do not allow for investigation of the initial stages of 
carcinogenesis, and the cancer-inducing agent is unknown. The UROtsa cell line 
originates from urothelial cells derived from the left ureter of a 12-year-old girl, which 
was then immortalized with a temperature-sensitive SV40 large T-antigen gene. UROtsa 
cell morphology resembls primary urothelial cells, growing in tightly packed colonies in 
the shape of irregular polygonal cells with a low nucleus to cytoplasmic ratio.  
Multinucleated and long fusiform cells ae observed at low frequency. The cells do not 
grow in soft agar and are unable to form tumors in nude mice, indicating that they are not 
neoplastically transformed. The cells were immortalized with a temperature-sensitive T-
antigen such that incubation at elevated temperature would reduce growth rates, possibly 
providing an in vitro model system that more closely resembled that of human 
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urothelium. The temperature-sensitive trait of the SV40 T-antigen was lost and UROtsa 
cell growth rate was unchanged at elevated temperatures (Petzoldt, Leigh, Duffy, Sexton, 
& Masters, 1995). Further, characterization proves that the immortalized UROtsa cell line 
is a close model of normal human epithelium, with the ability to resemble the 
intermediate or basal cell layer depending upon serum growth conditions.  
UROtsa cells cultured on serum-containing growth medium demonstrate a basal cell 
phenotype with a flattened appearance and grow as a monolayer with no tendency to 
stratify. The cells have numerous desmosomal connections and moderate lateral 
digitations, a high nuclear to cytoplasmic ratio, and presence of intermediate filaments. 
No tight junctions nor gap junctions are observed between the apical poles of the cells. 
UROtsa cells cultured on a serum-free growth medium resemble the transitional 
epithelium, with multilayered formations of cells, abundant intermediate filaments, and a 
more polarized epithelial morphology. The cells contain frequent desomosomal 
connection and extensive interdigitation. Freeze-fracture analysis reveals the presence of 
gap junctions and tight junction sealing strands between cells. The immortalized UROtsa 
cell line also expresses metallothioneins and heat shock protein profiles in agreement 
with in situ urothelial expression (M R Rossi et al., 2001).  
This lab was the first to malignantly transform urothelial cells with cadmium and 
arsenic in vitro, providing a model system for the confirmation of epidemiological studies 
and further investigation of carcinogenic mechanisms and biomarker identification. 
During transformation, both serum-fed and serum free cultures were used. Immortalized 
UROtsa cells were fed medium containing 1 µM sodium arsenite or cadmium chloride 
over a period of up to three months. Several rounds of cytotoxicity followed by regrowth 
22 
 
of remaining cells occurred, after which growth rates began to increase far in excess over 
the parental UROtsa cells. The transformed cells appeared morphologically similar to the 
parent, though the serum-free cultures lost the ability to stratify. The transformed cells 
formed colonies in soft agar, though the serum-fed cells were more efficient. 
Furthermore, UROtsa cells transformed by cadmium and arsenic in serum-free media 
were able to form tumors when injected subcutaneously into nude mice (Sens et al., 
2004). 
The tumor heterotransplants provide a useful tool for the study of arsenic- and 
cadmium-induced bladder cancer, as animal models for these cancers are difficult to 
produce. The subcutaneous tumor heterotransplants generated from arsenic-transformed 
cells are composed of infiltrating masses or nests of moderately differentiated cells, with 
differentiation increasing from the periphery towards the center of the masses. The tumor 
histology resembles that of invasive urothelial cell carcinoma along with regions of 
squamous differentiation. Tumors derived from the cadmium transformants are similar to 
the arsenic heterotransplants, but with less squamous differentiation (Sens et al., 2004). 
Global analysis of changes in gene expression in the transformed isolates allows for 
the investigation of metal-specific carcinogenic mechanisms and biomarkers for bladder 
cancer staging, and prediction of progression and recurrence. Multiple independently-
transformed isolates were subjected to microarray analysis; that is, additional isolates 
were derived from the parent UROtsa cell line with identical exposures (Garrett, Somji, 
Sens, & Zhang, 2014). Multiple independently-transformed isolates allow for assessment 
of variability and determination of commonly altered pathways, eliminating non-specific 
gene expression. Tumor heterogeneity is an important issue in cancer research, both 
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within individual tumors and within a single tumor (M Gerlinger & Swanton, 2010; 
Marco Gerlinger et al., 2014; Sjöblom, 2008). Furthermore, UROtsa cells metabolize 
inorganic arsenic to MMA(III) (Bredfeldt et al., 2004) and the different metabolites of 
arsenic may give rise to a variety of changes. By comparing and contrasting changes in 
gene expression in arsenic- and cadmium-transformed cells, the carcinogenesis pathways 
unique to each metal may be elucidated, as well as common mechanisms of bladder 
cancer progression. 
Subcutaneous tumors derived from arsenic-transformed UROtsa cells display a 
squamous phenotype, including expression of keratin 6 and 16 which are indicative of 
early features of squamous differentiation (Cao et al., 2010). Subcutaneous tumors 
derived from cadmium-transformed UROtsa cells display mild to prominent squamous 
differentiation, as well (Somji et al., 2010). Keratin-6a, a gene involved in urothelial 
proliferation and wound repair, is upregulated in cadmium-transformed UROtsa cells in 
vitro and in mouse heterotransplant tumors. In the normal UROtsa cell line, keratin-6a 
expression iss induced by insulin and EGF, suggesting that keratin-6a may be a marker 
for cancer cells with an activated growth factor pathway (Somji et al., 2008). Keratin 6, 
16, and 17 are correlated with areas of squamous differentiation in Cd heterotransplants. 
Subcutaneous tumors derived from arsenic-transformed UROtsa cells demonstrate 
intense focal staining for keratin 7 and 19. In general, cadmium and arsenic 
transformation of UROtsa cells display similar patterns of keratin 6, 7, 16, 17 and 19 in 
vitro and in tumors (Somji et al., 2011). Other studies have found that keratin 5/6 
expression may distinguish reactive urothelial atypia from urothelial carcinoma in situ 
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and the non-invasive compartment of high-grade papillary urothelial carcinoma 
(Edgecombe, Nguyen, Djordjevic, Belanger, & Mai, 2012). 
While metallothionein does not appear to play a large role in cancer initiation, its 
induction due to heavy metals may be valuable as a biomarker of cancer progression. 
Patterns of Metallothionein 1/2 in arsenic- and cadmium-transformed UROtsa 
heterotransplants are similar to that of human high-grade bladder cancers, which is focal 
in its expression (X. D. Zhou, Sens, Sens, et al., 2006). Metallothionein-3, which is 
expressed in 96% of high-grade urothelial cancers, is observed in tumor heterotransplants 
derived from arsenic- and cadmium-transformed UROtsa cells, as well (X. D. Zhou, 
Sens, Garrett, et al., 2006), indicating that the metallothionein proteins may be useful as a 
biomarker of high-grade bladder cancer. 
SPARC, a protein involved in extracellular matrix synthesis and the promotion of 
changes in cell shape, is decreased in arsenic- and cadmium-transformed UROtsa cell 
lines and subcutaneous tumor heterotransplants. While the epithelial component of cells 
is negative for SPARC, positive staining is observed in stromal cells. Negative epithelial 
with positive stromal expression of SPARC is confirmed in human bladder cancer 
specimens, as well (Jennifer Larson et al., 2010). In SPARC-null mice, development of 
urothelial preneoplasia, neoplasia, and metastasis is increased, along with a reduction in 
survival. SPARC also regulates chemical carcinogen-associated inflammation, ROS, and 
cell proliferation (Said, Frierson, Sanchez-Carbayo, Brekken, & Theodorescu, 2013). 
Neuron-specific enolase is induced in arsenic- and cadmium-exposed UROtsa cells, 
as well as the transformed cell lines and tumor heterotransplants, suggesting a role in 
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carcinogenesis. Protein expression was localized to the nucleus, suggesting alternatives to 
its commonly known role in glycolysis (Soh et al., 2012). 
Microarray analysis of the arsenic-transformed isolates reveal 328 genes commonly 
induced and 91 repressed that had at least two-fold change for each isolate compared with 
the control. In the cadmium-transformed isolates, 285 genes are commonly induced, with 
215 repressed. (Garrett et al., 2014). The microarray consisted of six arsenic-transformed 
and seven cadmium-transformed biological replicates. To assess statistical significance of 
the numbers of commonly induced and repressed genes, a simulation study was designed 
using randomly generated subsets of genes. The number of significantly induced or 
repressed genes in common to all isolates was counted, and a new subset of genes was 
then randomly selected. This simulation was performed 1,000,000 times, and the number 
of differentially expressed genes never surpassed that found by the microarray (Garrett et 
al., 2014).  
Validation by PCR array was then performed. Genes which demonstrated less than 
5% false discovery rate and greater than 3.2-fold change on the microarray were selected 
for validation. In the microarray, each biological replicate was tested in triplicate. Results 
from the PCR array were similar to those from the microarray, in which the percent of 
genes which failed to validate was similar to the 5% false discovery rate utilized in the 
microarray (Garrett et al., 2014). 
To determine whether the number of isolates used for microarray were sufficient to 
identify common gene sets, a model was developed to predict the number of commonly 
induced or repressed genes as the number of isolates increased. With the addition of each 
isolate, the number of common genes decreased. However, when the number of isolates 
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reached four or five (depending upon the sample set), the number of common genes 
stabilized, indicating that at this point the list of induced and repressed genes are truly 
responsive to the cadmium or arsenite treatment. As the cadmium- and arsenic-
transformed UROtsa cells contained seven and six isolates, respectively, it was 
determined that the commonly induced or repressed genes identified were responsive and 
specific (Garrett et al., 2014). 
Of the differentially induced genes confirmed by PCR in the arsenic-transformed 
isolates, N-cadherin was the top-most consistently induced gene. In cadmium-
transformants, N-cadherin is the 5
th
 most consistently induced gene (Figure 1.2) (Garrett 
et al., 2014). 
 
Figure 1.2 N-cadherin is consistently induced in As
3+
- and Cd
2+
-transformed 
UROtsa cells. PCR array validation of microarray results indicates N-cadherin is 
significantly induced in the majority of As
3+
-and Cd
2+
-transformed UROtsa isolates. PCR 
results represent Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, 
***p<0.001 
N-cadherin 
Cadherins are proteins that contribute to adherens junctions, named for their calcium-
dependent adhesive properties (Jäger et al., 2010). These Type 1 transmembrane proteins 
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mediate homophilic cell adhesion and include epithelial-cadherin (E-cadherin), neuronal-
cadherin (N-cadherin), placental-cadherin (P-cadherin), and retinal cadherin (van Roy, 
2014).  
N-cadherin is normally expressed in the brain, vascular endothelial cells, and cardiac 
and skeletal muscle cells. N-cadherin promotes the development of neuroepithelial 
adherens junctions, axon migration, and synapse formation (Takeichi, 2007). Expression 
of N-cadherin is a hallmark of the epithelial-to-mesenchymal transition (EMT), a process 
which occurs in numerous cancers and is believed to promote invasion and metastasis 
(Wheelock, Shintani, Maeda, Fukumoto, & Johnson, 2008).  
During EMT, E-cadherin expression is often lost or decreased, leading to 
destabilization of adherens junctions and loss of apical-basal polarity (C. Huang, Ke, 
Costa, & Shi, 2004). E-cadherin is the main cadherin that promotes cell-cell adhesion and 
polarity in epithelial tissues, supporting their differentiated state (Capaldo & Macara, 
2007; Gumbiner, Stevenson, & Grimaldi, 1988). E-cadherin also sequesters β-catenin, 
preventing activation of the Wnt signaling pathway and expression of oncogenes such as 
cyclin D1 (Bryan & Tselepis, 2010). As such, the loss of E-cadherin expression in 
bladder cancer is associated with increased stage, grade, and incidence of recurrence and 
with decreased survival rate (Baumgart et al., 2007; B. Liu, Miyake, Nishikawa, & 
Fujisawa, 2015; Muramaki et al., 2012; Muramaki, Miyake, Terakawa, Kusuda, & 
Fujisawa, 2011; K M Rieger-Christ et al., 2001; Shimazui et al., 1996; Zhao, Dong, Sun, 
Zhang, & Sun, 2014). 
Additional changes include loss of other adhesion complexes and alterations in 
morphology due to cytoskeletal restructuring (Lamouille, Xu, & Derynck, 2014). Cell 
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motility is increased, facilitated by an enhanced ability to degrade extracellular matrix 
proteins. Resistance to senescence and apoptosis is also elevated (Thiery, Acloque, 
Huang, & Nieto, 2009). 
N-cadherin expression during EMT promotes cell affinity for the extracellular matrix 
and endothelial compartment, promoting cell survival and transendothelial migration 
(Groen et al., 2011; Qi, Chen, Wang, & Siu, 2005). N-cadherin also interacts with and 
stabilizes fibroblast growth receptors at the cell surface, enhancing its activity and 
altering the downstream MAPK/ERK pathway leading to increased invasion (Suyama, 
Shapiro, Guttman, & Hazan, 2002). 
N-cadherin expression has been positively correlated with bladder cancer progression 
and recurrence. In a study of 161 bladder cancer patients, N-cadherin expression levels 
are correlated with tumor recurrence following removal of non-muscle-invasive 
urothelial carcinoma of the bladder (B. Liu et al., 2015). In another study of 115 patients 
with non-muscle-invasive bladder cancer following tumor removal, positive N-cadherin 
expression is significantly associated with bladder cancer recurrence and significant 
reduction in recurrence-free survival. Incidence of recurrence is significantly increased in 
E-cadherin-negative and N-cadherin-positive tumors, and recurrence-free survival is 
reduced (Muramaki et al., 2012). Recurrence-free survival is associated with negative N-
cadherin expression in a study of urothelial carcinoma of the upper urinary tract after 
removal of parts of the bladder and kidney (Muramaki et al., 2011). Lascombe et al. 
examined N-cadherin expression in 101 tumors and found that mRNA expression is 
increased in muscle-invasive versus superficial tumors, but comparable protein levels are 
not detected (Lascombe et al., 2006). A study of 181 bladder cancer patients stratified by 
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tumor invasiveness found that N-cadherin expression negatively correlates to survival in 
all cases, but positively associates with survival in invasive cases (Jäger et al., 2010), and 
no correlation is found between N-cadherin and stage, grade, lymph node involvement or 
vascular invasion in a study of 572 bladder cancer patients (Baumgart et al., 2007). 
Numerous transcription factors regulate the epithelial-to-mesenchymal transition, 
including Twist, Snail, Slug, Zeb1, and Zeb2 (Lamouille et al., 2014). Differential 
expression of Twist, a repressor of E-cadherin, has been noted in bladder cancer, in 
which elevated Twist expression is correlated with bladder cancer stage, grade, and 
poorer progression-free survival (Fondrevelle et al., 2009). The roles of other EMT 
transcription factors in bladder cancer have not been fully elucidated. In a recent 
immunohistochemical study of transcription factors in 49 samples of urothelial 
carcinoma, Snail is correlated with local invasiveness, while Slug is associated with both 
local and muscle invasion capacity, as well as metastasis. Zeb1 is significantly related to 
invasiveness, but not metastasis (Schulte et al., 2012). 
MicroRNAs also regulate EMT, particularly the miR-200 family which promotes the 
epithelial phenotype and has been explored in bladder cancer. miR-200c is down-
regulated in bladder cancer specimens in a study by Liu et al., and its overexpression 
results in decreased cell invasion, migration, and proliferation capabilities (L. Liu et al., 
2014). In another study, miR-200 family mRNAs are expressed in bladder cancers 
displaying an epithelial phenotype, and the transcription factors Zeb1 and 2 are inversely 
correlated with miR-200c expression. Further, miR-200c reverts EMT, inducing the 
mesenchymal bladder cancer cell line UMUC3 to undergo epithelial differentiation, 
further validating the role of miR-200c as a negative regulator of EMT (Adam et al., 
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2009). Loss of miR-141 and miR-200b is associated with increased invasion and 
migration, Vimentin and N-cadherin expression, downregulated E-cadherin, and 
increased metalloproteases in a study performed with the UM-UC-3 and HTB 9 bladder 
cancer cell lines (W. Liu et al., 2015). 
The EMT status of some human bladder cancer cell lines has been characterized, 
though a common pattern of EMT progression has not been clarified. The cell lines RT4 
and RT112 demonstrate an epithelial phenotype and morphology, with low to no 
expression of the mesenchymal markers N-cadherin and Vimentin (Matsui et al., 2012). 
The bladder cancer cell lines 5367 and 253J BV display both epithelial and mesenchymal 
characteristics, with co-expression of N-cadherin and E-cadherin. Cell line 5367 
demonstrates high levels of the pro-EMT transcription factor Slug but low expression of 
Vimentin, while 253J BV has low Slug expression accompanied with high Snail levels, 
another pro-EMT transcription factor, and is positive for Vimentin (Hänze, Henrici, 
Hegele, Hofmann, & Olbert, 2013; Matsui et al., 2012; Wu et al., 2012). TCCSUP lacks 
E-cadherin, with a moderate increase in N-cadherin expression. Vimentin is low in this 
cell line, though it demonstrates mesenchymal morphology (Baumgart et al., 2007; Hänze 
et al., 2013; Matsui et al., 2012). Cell lines J82 and T24 are the most mesenchymal, 
showing a loss of E-cadherin accompanied by increased N-cadherin, as well as Vimentin 
expression (Wu et al., 2012). Both cell lines demonstrate increased cell invasion capacity, 
with T24 the highest (Wallerand et al., 2010). 
Very little is known about the regulation of N-cadherin. A few transcription factors 
have been investigated in the regulation of N-cadherin, though not in the context of 
urothelial tissue expression. The transcription factor Twist, a basic helix-loop-helix 
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protein and well-known repressor of E-cadherin expression, may also activate 
transcription of N-cadherin. In a study by Alexander et al. in prostate cancer cells, Twist 
depletion results in a decrease in N-cadherin expression. Using a luciferase assay, co-
expression of Twist and the 5’ promoter construct for N-cadherin shows no increase in 
promoter activity. However, co-expression of Twist with an E-box sequence within the 
first intron of N-cadherin results in significant increases in promoter activity. Further 
analysis by electrophoretic mobility shift assay reveals Twist binding at +2,627, within 
the first intron of N-cadherin (Alexander et al., 2006). This regulation displays similarity 
with that of E-cadherin, which is regulated at the first and second introns in vivo 
(Stemmler, Hecht, Kinzel, & Kemler, 2003). Further evidence of dual regulatory function 
is seen in the activation of YB-1 and AKT-2 by Twist (Cheng, Zhang, & Wang, 2008; 
Shiota et al., 2008). The mechanisms that underlie its dual transcriptional mode are not 
fully elucidated, though recruitment of epigenetic factors have been implicated (F. Yang 
et al., 2012). 
Activating protein 1 (AP-1), a heterodimer formed of c-Jun and c-Fos, is another 
potential transcription factor regulating N-cadherin expression. AP-1 regulates 
transcription of N-cadherin in Schwannoma cells (Martiáñez, Lamarca, Casals, & Gella, 
2013). Further, AP-1 activity may be altered in urothelial cells by arsenic exposure. 
Exposure to four weeks of sodium arsenite in mice induces hyperplasia of the bladder 
urothelium and an increase in DNA binding of AP-1. In transgenic mice containing an 
AP-1 luciferase reporter, arsenite exposure promotes AP-1 transactivation. In vitro 
experiments using a human bladder epithelial cell line also demonstrate increased AP-1 
DNA binding following arsenite treatment (Simeonova et al., 2000, 2001). In addition, 
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exposure to methylarsine oxide or iododimethylarsine promotes phosphorylation of c-Jun 
and AP-1 DNA binding, and was found to be more potent than arsenite in promoting AP-
1 activity (Drobná, Jaspers, Thomas, & Stýblo, 2003). 
NFĸB may also regulate N-cadherin transcription. Electrophoretic mobility shift 
assays for NFĸB DNA binding reveal strong binding activity at the N-cadherin promoter 
in melanoma cells. Reporter gene assays showed that NFĸB binding activates N-cadherin 
transcription (Kuphal & Bosserhoff, 2006). In UROtsa cells, MMA(III) exposure induces 
the translocation of NFĸB to the nucleus, suggesting that arsenic may induce N-cadherin 
expression through NFĸB to promote bladder cancer progression (Escudero-Lourdes, 
Medeiros, Cárdenas-González, Wnek, & Gandolfi, 2010). 
The transcription factors specificity protein 1 (SP1) and 2 (SP2) show evidence of 
regulatory function, as well. Electrophoretic mobility shift assays in human osteoblasts 
indicate that an Sp1/Sp3 binding site regulates N-cadherin expression. Specifically, Sp3 
antagonizes Sp1-induced transcription (Le Mée, Fromigué, & Marie, 2005). In a series of 
experiments studying the anti-proliferative, anti-angiogenic, and pro-apoptotic activity of 
arsenic trioxide in bladder cancer cells, arsenite-responsive cell lines displayed oxidative 
stress-dependent decreases in Sp1, Sp3, and Sp4 expression. A number of additional 
studies in other cell types have also found downregulation of Sp1 following arsenic 
exposure (Ai et al., 2007; Chou et al., 2005; Y. Zhang et al., 2015). Cadmium is also 
associated with reduced Sp1 activity (Aiba, Hossain, & Kuo, 2008; Kothinti, Blodgett, 
Tabatabai, & Petering, 2010; Y. Li, Kimura, Huyck, Laity, & Andrews, 2008; Watkin, 
Nawrot, Potts, & Hart, 2003; Youn et al., 2005), suggesting that Sp1 and/or Sp3 may 
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mediate arsenic- and cadmium-induced alterations in N-cadherin expression in the 
progression of bladder cancer. 
Other transcription factors shown to have regulatory activity at the N-cadherin 
promoter include RBPJ (Fangfei Li et al., 2011), GATA-4 (H. Zhang, Toyofuku, Kamei, 
& Hori, 2003), SOX-9 (Panda, Miao, Lefebvre, Hendy, & Goltzman, 2001), MZF1 (Le 
Mée et al., 2005), and SMAD4 (Kang et al., 2014). However, these transcription factors 
have not been associated with bladder cancer progression or arsenic and cadmium 
exposure.  
Bladder Cancer Characteristics and Research Needs 
In 2011, it was estimated that 571,518 individuals were living with bladder cancer in 
the United States (Howlader et al., 2014). 74,690 new cases of bladder cancer were 
estimated for 2014 in the United States, with 15,580 deaths due to the disease (Malats & 
Real, 2015). Bladder cancer is the 9
th
 leading cause of death in the United States. The 
median age at diagnosis is 73, with bladder cancer more common in men than women 
(Howlader et al., 2014). The annual cost of bladder cancer was $4 billion in the United 
States. when estimated in 2010, and it is predicted to rise to $5 billion by 2020 (Yeung, 
Dinh, & Lee, 2014). 
The bladder is composed of a mucosa lined by transitional epithelium, muscularis, 
and adventitia. The number of layers of the transitional epithelium can vary from six 
when the bladder is empty, to three when the bladder is distended. (Ross & Pawlina, 
2011). The urothelium consists of a basal layer, intermediate layer, and superficial layer, 
with cells increasing in differentiation from base to surface. Extensive interdigitations of 
cytoplasmic processes and desmosomes create lateral connections throughout, while 
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superficial cells are linked by tight junctions to create an impermeable barrier (Jost, 
Gosling, & Dixon, 1989). The superficial, or umbrella cells, are usually cuboidal and 
bulge into the lumen. Further, in the distended bladder, umbrella cells flatten and unfold 
to increase available surface area. The normal urothelium has a very low proliferative 
capacity, wherein basal cells act as progenitors. Upon pathological damage, both basal 
and intermediate cells will rapidly regenerate the urothelium (Ho, Kurtova, & Chan, 
2012). Underlying the transitional epithelium is the lamina propria, a dense collagenous 
layer, followed by the muscularis. The muscularis contains longitudinal and circular 
layers of smooth muscle which aid the movement of urine through the ureter to the 
bladder (Ross & Pawlina, 2011).  
The majority of bladder cancers are transitional cell carcinoma, with less than ten 
percent composed of squamous cell carcinoma and adenocarcinoma. Small cell 
carcinoma and sarcoma of the bladder are rare (Cubilla et al., 2004). Transitional cell 
carcinoma is widely categorized by the extent of its invasion into surrounding tissue. 
There are two types of non-muscle-invasive transitional cell neoplasms: flat and papillary 
lesions. Of the flat lesions, carcinoma in situ is a known precursor of invasive cancer. 
This lesion contains cells with irregular, large, hyperchromatic nuclei (See Figure). Most 
patients have multifocal or diffuse carcinoma in situ cells (Figure 1.2.A). Papillary 
lesions often occur in multiples, and frequently recur following local resection (Figure 
1.2.B). Patients with a history of papillary tumors are at risk for developing invasive 
carcinoma (Al-ahmadie, Lin, & Reuter, 2011). The grading of papillary neoplasms is 
widely debated, but the current system is based on architectural and cytologic changes in 
the urothelium. With increasing grade, papillary carcinoma progression rates are 
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elevated. Invasive urothelial carcinoma includes tumors which invade the muscularis 
mucosae or the muscularis propria (Figure 1.3). These tumors have variable histology, 
though depth of invasion is important for staging (Cubilla et al., 2004).  
 
Figure 1.3 In situ and papillary urothelial carcinoma. A) Urothelial carcinoma in situ 
and B) Papillary urothelial neoplasm of low malignant potential. Adapted from (Al-
ahmadie et al., 2011). 
 
Squamous cell carcinoma is characterized by keratin pearls, intercellular bridges, and 
keratotic cellular debris. At the time of diagnosis, most squamous cell carcinomas are 
poorly differentiated and deeply invasive, possibly contributing to the poor prognosis of 
these tumors (Al-ahmadie et al., 2011).  
Seventy percent of bladder cancers are confined to the bladder and are non-muscle-
invasive. While only 5-10% of those will progress and infiltrate the bladder, half of non-
invasive bladder cancers will recur (Simon et al., 2004). 
Cancer grade is a prediction of cancer progression, while stage characterizes tumor 
size and spread. The American Joint Committee on Cancer designated 6 stages of bladder 
cancer (0a, 0is, I, II, III, and IV) determined by tumor type (papillary or in situ and extent 
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of bladder invasion), presence of lymph node metastasis, and indication of distant 
metastasis (Rubin & Hansen, 2012). 
 
Figure 1.4 Varying levels of invasive urothelial carcinoma. A) Invasion into lamina 
propria. B) Invasion into deep lamina propria. B) Invasion into muscularis propria. 
Adapted from (Al-ahmadie et al., 2011). 
 
 The most common symptom of bladder cancer is painless hematuria. Cystoscopy 
is the gold standard for evaluation of bladder cancer, in which tumor location, size, and 
appearance is determined (Kamat et al., 2013). Transurothelial resection or biopsy is then 
performed for histological examination of cancer type and stage. Cytology is also used 
for detection of high grade cancer and to monitor patients for recurrence following 
treatment. In cytology, cells found in urine are analyzed for abnormalities indicating 
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neoplasia. The clinical value of cytology for the management of urothelial cancer is 
variable, as it only has strong sensitivity in high-grade bladder cancers (Al-ahmadie et al., 
2011).   
Bladder cancer has the highest lifetime cost per person (Yeung et al., 2014), with 
60% of costs due to surveillance and treatment of recurrence (Avritscher et al., 2006). 
Surveillance has been identified as a target for improvement in economical efficacy 
(Svatek et al., 2014). Tumor biomarkers may be a promising route to determining bladder 
cancer recurrence. Tumor biomarkers do not add additional invasive procedures, as 
analysis utilizes previously resected tumors. Upon initial tumor resection, evaluation of 
biomarkers could provide information about potential recurrence, reducing the number of 
cystoscopies and allowing for earlier detection of tumor recurrence (Lotan et al., 2010). A 
number of tissue-based biomarkers have been developed, though none are yet ready for 
use in clinical settings (Kamat et al., 2013). 
Hypothesis and Rationale 
This body of work tests the hypothesis that As
3+
 and Cd
2+
 induce bladder cancer 
through EMT mechanisms. In the first study, the role of N-cadherin, a pro-EMT marker, 
in bladder cancer caused by As
3+
 and Cd
2+
 will be determined both in vitro and in animal 
models. The finding that N-cadherin was the top-most consistently induced gene in 
arsenic transformed UROtsa cells and a top induced gene in cadmium transformed 
isolates suggests that the gene may play an instrumental role in the process of malignant 
transformation, and that it could be developed as a biomarker of heavy metal-induced 
bladder cancer. The fact that N-cadherin expression is maintained in transformants 
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following removal of arsenic and cadmium also implies a mechanism of permanent gene 
activation, and the role of epigenetic regulation will be explored. 
 To further establish the role of EMT in As
3+
- and Cd
2+
- induced bladder cancer, 
additional markers of the transition will be characterized. While EMT is considered the 
mechanism by which cancers progress and become metastatic, the details of the process 
are unique to cell type and inducing agent, and have not been elucidated in bladder 
cancer.  
 The As
3+
- and Cd
2+
 transformed UROtsa cell lines are a valuable tool for 
distinguishing the characteristics of bladder cancer induced by heavy metals. Further, this 
model system demonstrates metal-specific EMT mechanisms of bladder cancer 
progression. With these tools at hand, sensitive and specific biomarkers may be 
elucidated to better detect and predict bladder cancer progression.
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CHAPTER II 
METHODS 
Cell Culture 
The human urothelial cell line UROtsa was immortalized and cultured as 
described in Rossi et al. 2001. Briefly, cells were grown in 75 cm
2
 cell culture flasks with 
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco) supplemented with 5% v/v fetal 
calf serum (Gibco). Cells were maintained at 37 
o
C in a 5% CO2/95% air atmosphere. 
Upon reaching confluency, cells were subcultured at a 1:3 ratio with 0.25% trypsin/ 
EDTA (Gibco). Cells were fed every three days with growth medium. 
UROtsa cells were transformed with arsenite and cadmium as previously 
described (Sens et al., 2004). Briefly, UROtsa cells were cultured under identical 
conditions and transformed with 1µM cadmium chloride and sodium (Sigma-Aldrich) in 
the media. Cells were harvested periodically throughout the transformation. The resulting 
seven Cd
2+
 and six As
3+
 isolates were expanded ten times at a 1:20 ratio before use. All 
isolates were able to form colonies in soft agar as described in Sens et al. 2004. Cells 
were maintained in DMEM supplemented with 5% fetal calf serum and 1% glucose and 
subcultured at a 1:10 ratio. 
 Human bladder cancer cell lines J82, RT4, and TCCSUP were purchased from 
ATCC and cultured in DMEM with 10% fetal calf serum,1% glucose, and 2.5% 
nonessential amino acids.
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For short-term heavy metal exposure experiments, the parent UROtsa cell line 
was passaged with DMEM containing 1 µM sodium arsenite or cadmium chloride for 30 
days. Cells were harvested for PCR and Western blot analysis at each passage. 
Microspheres were derived from cell monolayer cultures by seeding at low 
density on low-adherance flasks. The parent UROtsa cells were grown in serum-free 
DMEM, and transformed isolates were cultured in 20/12 media.
AZC and HDACi 
Parent UROtsa cells were seeded 1:10 and treated the following day with 5-Aza-2’-
deoxycytidine (5-AZC) (Sigma-Aldrich) or MS-275 (ALEXIS Biochemicals). Cells were 
exposed to 0.5, 1, 1.5 and 3 µM 5-AZC or 1, 3, and 5 µM MS-275 for three days. Upon 
reaching confluency, cells were harvested for PCR analysis. 
Heterotransplant Tumors 
Heterotransplant tumors were formed by subcutaneous (SC) injection of the 
transformed isolates in nude mice as described in Sens et al. 2004. In short, NCr-nu/nu 
mice were inoculated with 1 x 10
6
 cells in 0.2 ml phosphate-buffered saline. Mice were 
sacrificed after 10 weeks or if conditions warranted euthanasia. Individual tumors were 
split for RNA isolation, protein isolation, and immunohistochemistry. 
To observe the ability of tumors to colonize internal organs of the peritoneum, 
transformed cells were implanted into nude mice via intraperitoneal injection as 
described in Cao et al. (2010). Briefly, 1 x 10
6
 cells in phosphate-buffered saline (PBS) 
were injected into the lower right quadrant of the abdominal cavity. Mice were 
euthanized 53 days later when tumors became visible and large in some mice. Following 
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necropsy, tumors and their associated organs were formalin fixed and paraffin embedded 
for histology or flash frozen for molecular techniques. 
Real Time RT-PCR 
Total RNA was isolated using the TRI Reagent protocol (Molecular Research Center, 
Inc.) and quantified by spectrophotometry (Nanodrop). Tumor samples were snap frozen 
and ground to a powder with liquid nitrogen before RNA isolation. 
One hundred ng of purified RNA was subjected to cDNA synthesis using the iScript 
cDNA synthesis kit (Bio-Rad) in a total volume of 20 µl. Real time PCR was performed 
with SYBR Green (Bio-Rad) using 10 ng of cDNA. Amplification was performed using 
the iCycler MyiQ real time detection system (Bio-Rad) and measured by SYBR Green 
fluorescence. Primers used are indicated in Table 2.1. 
Gene Company Catalog No. 
ALDH1A1 Qiagen QT00013286 
CD44 Qiagen QT00073549 
CDH1 BioRad qHsaCED0042076 
CDH2 Qiagen QT00063196 
eEF1A2 BioRad qHsaCID0011054  
EPHA4 BioRad qHsaCID0017961 
ETV7 BioRad qHsaCED0037660 
IL1RN BioRad qHsaCID0014491 
LIMCH1 BioRad qHsaCID0010779 
LPHN2 BioRad qHsaCID0010674 
NR2F1 BioRad qHsaCED0047128 
NR2F2 BioRad qHsaCID0015621  
NTF3 BioRad qHsaCED0004155 
OCLN BioRad qHsaCED0038290 
Slug Qiagen QT00044128 
Snai1 Qiagen QT00010010 
STEAP1 BioRad qHsaCED0046236 
TCF4 Qiagen QT00031829 
Twist Qiagen QT00011956 
UGT8 BioRad qHsaCID0017816 
Vimentin BioRad qHsaCID0012604 
Zeb1 Qiagen QT01888446 
Zeb2 Qiagen QT01867586 
Table 2.1 Primer source information 
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Levels of gene expression were determined using quantitative and relative standard 
curves. Samples were normalized to β-actin (forward, 5-
CGACAACGGCTCCGGCATGT-3 and reverse, 5-TGCCGTGCTCGATGGGGTACT-
3). The resulting levels were then expressed as fold change over the parent UROtsa cell 
line.  
Analysis of PCR results was performed by one-way analysis of variance (ANOVA) 
and Tukey or Dunnett’s post-test. Data was represented as mean SEM of triplicate 
determinations with *p<0.05, **p<0.01, and ***p<0.001. GraphPad Prism 5 was used for 
all analyses. 
Western Blot Analysis 
Total protein was isolated from cell pellets and tumor tissue using 2% SDS 50 mM 
Tris-HCl, pH 6.8 with 1% protease inhibitor cocktail (Sigma-Aldrich). Tissue was frozen 
and ground to powder with liquid nitrogen before homogenizing in lysis buffer. Samples 
were boiled for 10 min followed by DNA shearing by sonication. Protein concentration 
was determined by BCA assay (Pierce). Samples were stored at -80 
o
C in 100 mM 
dithiothreitol.  
Fifteen µg protein was separated by SDS-PAGE using the TGX AnyKd SDS 
polyacrylamide gel (BioRad). Samples were reduced in β-mercaptoethanol and boiled for 
5 min prior to loading. Protein was transferred to a 0.2 µm PVDF membrane using the 
semi-dry technique followed by blocking in 5% nonfat dry milk in TBS-T for 90 min. 
Blots were incubated overnight at 4 
o
C in the primary antibodies N-cadherin (Invitrogen, 
cat# 333900, 1:1,000), E-cadherin (Santa Cruz, sc-7870, 1:1,000), β-actin (AbCam, 
ab8226, 1:1,000), eEF1A2 (Abnova, H00001917-A01, 1:1,000) and NT-3 (Santa Cruz, 
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sc-547, 1:200). Blots were probed with appropriate HRP-conjugated secondary 
antibodies (Cell Signaling) and visualized using Clarity Western ECL (BioRad). 
Immunofluorescence 
 Parent UROtsa and transformed cells were cultured in 24-well plates containing 
12 mm coverslips. Confluent cultures were fixed in ice-cold 100% methanol for 3-5 min 
at -20 
o
C. Cells were then incubated in rabbit α-human E-cadherin primary antibody 
(Santa Cruz, sc-7870) at 2 µg/ml followed by incubation with 2 µg/ml of goat α-rabbit 
Alexa Fluor 594-tagged secondary antibody (Invitrogen, A11012). Cells were then 
incubated with mouse α-human N-cadherin primary antibody at 10 µg/ml followed by 2 
µg/ml goat α-mouse secondary antibody Alexa Fluor 488 (Invitrogen, A11001). All 
antibody incubations were done at 37 
o
C for 45 min each. Images were captured with a 
Leica DM5500 Q TCS SPE confocal system and Z-slices were imaged at the indicated 
optimal depth, stacked and processed using LAS-AF software and Adobe Photoshop. 
Immunohistochemistry 
Serial sections of subcutaneous and intraperitoneal tumors were cut at 3-5 µm for 
use in immunohistochemical protocols. The primary antibodies used were: polyclonal 
rabbit α-E-cadherin (Santa Cruz, 1:100), monoclonal mouse α-N-cadherin (Invitrogen, 
1:100) and polyclonal rabbit α-Snail (Cell Signaling, 1:100).  Immunohistochemical 
staining was performed on Leica Bond-Max Automated IHC Staining System (Leica, 
Bannockburn, IL). Paraffin sections were processed in the machine from 
deparaffinization until counterstaining by hematoxylin according to the manufacturer’s 
recommended program with modification. Bond Polymer Refine Detection (Leica, 
DS9800) was used as the main reagents in the automatic staining process. Briefly, the 
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major steps includes deparaffinization, antigen retrieval in Bond Epitope Retrieval 
Solution 1 (Leica, Catalog No AR9961) for 20 min, peroxide block for 5 min, incubation 
with primary antibodies for 25 min at room temperature, incubation with Post Primary for 
10 min, incubation with Polymer for 10 min, visualization with DAB for 10 min, and 
counterstaining with hematoxylin for 5 min. Slides were rinsed in distilled water, 
dehydrated in graded ethanol, cleared in xylene, and coverslipped.  The presence and 
degree of immunoreactivity in the specimens was judged by two pathologists.  The scale 
used was 0 to +3 with 0 indicating no staining, +1 staining of mild intensity, +2 staining 
of moderate intensity, and +3 staining of strong intensity. 
Chromatin Immunoprecipitation 
The ChIP-IT
TM
 Express kit from Active Motif was used for chromatin 
immunoprecipitation experiments. UROtsa parent cells were passaged five times in 1 µM 
cadmium chloride or sodium arsenite, followed by 48 hr exposure to MS-275 or 5-AZC. 
Cells were grown to confluency in 75 cm
2
 flasks and fixed with 1% formaldehyde for 10 
min. Cross linking was stopped with 0.125 M glycine stop solution and cells were 
scraped with 2 ml PBS containing Phenylmethylsulfonyl fluoride (PMSF). Cells were 
pelleted and resuspended in ice-cold lysis buffer, and homogenized using an ice-cold 
dounce homogenizer. Nuclei were pelleted and resuspended in digestion buffer 
containing PMSF and protease cocktail inhibitor. Chromatin was then sheared using 
enzymatic shearing cocktail at 37 
o
C for 5 min, resulting in chromatin fragments of 200-
1,500 bp. Protein G-coated magnetic beads were incubated with 7 µg sheared chromatin 
and 3 µg antibody overnight at 4 
o
C. Antibodies for trimethylated Histone 3 Lysine 9 
(Active Motif), trimethylated H3K27 (Active Motif), and anti-acetyl Histone 4 
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(Millipore). Samples were washed and the immune complex was then eluted. 
Crosslinking was reversed using crosslinking buffer, and DNA was analyzed by 
conventional PCR using the Gene Amp PCR core kit (Applied Biosystems). Primers 
were designed for two regions of the N-cadherin promoter. Region 1 targeted a 72 bp 
sequence using forward primer, 5- CGGCCCGCTATTTGTCATCAGCTC-3 and reverse,   
5-CTCCCCACCCCCTTCTTCGC-3. An annealing temperature of 6 2
o
C was used for 
Region 1. Region 2 targeted a 84 bp sequence using forward primer  
5-ACGAGCCCGAAACCTCGCGTG-3 and reverse primer  
5- ACCTTGGCCGGTGGAGGATGTGGA-3 with an annealing temperature of 61 
o
C. 
PCR products were run on gel electrophoresis and band optical density was quantified 
using Image Lab software (BioRad). Results were normalized to the amount of 
corresponding DNA sequence from the fragmented chromatin solution prior to 
precipitation.  
Flow Cytometry 
Cells were dissociated in 0.1% trypsin, 0.5mM CaCl2 in PBS followed by 0.5 ml 
10 mM EDTA. Non-specific staining was blocked using 1% bovine serum albumin 
(BSA) for 15 min on ice. Phycoerythrin (PE)-conjugated N-cadherin (mouse mAb clone 
8C11, Biolegends cat # 350806) was added to cells at 1:10 and incubated at 4 
o
C in the 
dark for 30 min. Samples were washed two times in 0.1% BSA in PBS buffer before flow 
cytometry analysis. Cells were counted with a BD LSRII using FACSDiva software. 
Results were gated to exclude doublets and identify the singlet population
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CHAPTER III 
RESULTS 
N-cadherin Induction in As
3+
- and Cd
2+
-transformed UROtsa Cells 
To confirm the induction of N-cadherin observed by microarray, real time RT-
PCR was performed in the As
3+
 and Cd
2+
 isolates. Expression was found to be 
significantly elevated compared to the non-malignant parent UROtsa cell line in the 
majority of isolates. N-cadherin was induced an average of 20-fold in As
3+
 transformants, 
and 5 to10-fold in Cd
2+
 isolates (Figure 3.1.A, B). Western blot analysis showed protein 
levels comparable to that of mRNA (Figure 3.1.C, D). 
 
Figure 3.1 N-cadherin expression is elevated in As
3+
- and Cd
2+
-transformed UROtsa 
cells. Real time RT-PCR analysis of N-cadherin in parent UROtsa cell line and A) As
3+
 
isolates, and B)  Cd
2+
 isolates expressed as fold change normalized to β-actin. Western 
blot analysis of N-cadherin protein in A) As
3+
 isolates, and  D) Cd
2+
 isolates. PCR results 
represent Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, ***p<0.001 
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Immunofluorescence experiments were performed using a subset of the As
3+
- and 
Cd
2+
-transformed isolates. Results showed that N-cadherin was localized to the plasma 
membrane (Figure 3.2), with the most staining observed in isolate As#6 (Figure 3.2.D). 
N-cadherin staining was only observed at regions of cell-cell contact (Figure 3.3). The 
parent UROtsa cell line showed positive staining in a very small percentage of cells 
(Figure 3.2.A), while no N-cadherin staining was observed in Cd
2+
 #7 (data not shown). 
 
Figure 3.2 N-cadherin is highly expressed in As
3+
 isolate #6. N-cadherin expression is 
localized to the plasma membrane. Immunofluorescence staining for N-cadherin in A) 
parent UROtsa cells, B) Cd#1, C) As#3, and D) As#6. Cd#4 was also stained for N-
cadherin, but showed no positive labeling. Bar= 25 µM. 
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Figure 3.3 N-cadherin is expressed at cell-cell junctions. In N-cadherin-positive cells, 
the protein is localized to regions of cell-cell contact. Image A represents highly 
confluent As#6 cells with N-cadherin expression on all sides of the cell. Image B displays 
a region of less confluent As#6 cultures in which N-cadherin localization is evident only 
at regions of cell-cell contact.  
 
 Expression of N-cadherin was then measured in tumors formed by subcutaneous 
(SC) injection of transformed isolates into nude mice. Surprisingly, N-cadherin was not 
maintained in the subcutaneous heterotransplants at the mRNA or protein level (Figure 
3.4). Immunohistochemical staining was also negative for N-cadherin in both As
3+
- and 
Cd
2+
-transformed tumors (Figure 3.5, 3.6). The tumor cells were negative for N-
Cadherin, but the stromal cells showed focal weak staining of N-Cadherin. The staining 
of N-Cadherin in As#2 was a little stronger than other groups (Figure 3.5.B), while As#5 
was almost negative (Figure 3.5.E). Some strongly positive structures are non-specific 
signal. N-cadherin was then investigated in tumors derived from intraperitoneal (IP) 
heterotransplants, in which positive focal staining was seen (Figure 3.7). 
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Figure 3.4 N-cadherin mRNA and protein levels are unchanged in subcutaneous 
heterotransplant tumors derived from As
3+
- and Cd
2+
-transformed isolates. A) Real 
time RT-PCR analysis of N-cadherin in A) parent UROtsa cell line and As
3+
 isolates, and 
B) parent UROtsa cell line and Cd
2+
 isolates expressed as fold change normalized to β-
actin. C) Western blot analysis of N-cadherin protein in C) As
3+
 isolates, and D) Cd
2+
 
isolates. PCR results represent Mean ±SEM of triplicate determinations. *p<0.05, 
**p<0.01, ***p<0.001 
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Figure 3.5 Immunohistochemical analysis demonstrates negative staining in 
subcutaneous heterotransplant tumors derived from As
3+
-transformed isolates. The 
tumor cells are negative for N-Cadherin, but the stromal cells show focal weak staining 
of N-Cadherin. The staining of N-Cadherin in As #2 is a little stronger than other groups, 
and As#5 is almost negative. Some strongly positive structures are non-specific signal. A) 
As#1, B) As#2, C) As#3, D) As#4, E) As#5, F) As#6. Magnification 200X.  
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Figure 3.6 Immunohistochemical analysis demonstrates negative staining in 
subcutaneous heterotransplant tumors derived from Cd2+- transformed isolates. The 
tumor cells in Cd2+ tumors are negative for N-Cadherin, but the stromal cells show focal 
weak staining of N-Cadherin. Some strongly positive structures are non-specific signal.  
A) Cd#1, B) Cd#2, C) Cd#3, D) Cd#4, E) Cd#5, F) Cd#6, G) Cd#7. Magnification 200X. 
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Figure 3.7 N-cadherin is focally expressed in intraperitoneal tumors. In contrast to 
subcutaneous tumors, the all 3 IP tumors show focal weak staining of N-Cadherin. The 
strongly N-Cadherin positive round structures are non-specific staining. A) As#1, B) 
As#3, C) Cd#1. Magnification 200X  
 
 Cell population heterogeneity may be a cause of the inconsistent results for N-
cadherin expression in vivo. During transformation, numerous phases of massive die-off 
followed by regrowth of surviving colonies occurred, allowing the opportunity for some 
heterogeneity in the population to arise. To investigate whether the lack of a clonal 
population played a part in tumor phenotype, flow cytometry was performed for N-
cadherin among isolates with varying N-cadherin expression as observed by PCR and 
Western blot. The As
3+ 
isolates #1, #3, and #6 were chosen for their low, moderate, and 
high expression of N-cadherin protein, respectively (Figure 3.1.C). The Cd
2+
-transformed 
isolates #4, #1, and #5 similarly demonstrated low, medium, and high N-cadherin protein 
relative to parent UROtsa cells in previous experiments (Figure 3.1.D). Flow cytometric 
analysis using PE-conjugated N-cadherin antibody indicated a dramatic increase in the 
percent of cells positive for N-cadherin in  As
3+
 isolate #6 alone (Figure 3.8, Table 3.1), 
with 98.5% of cells positive for N-cadherin in isolate #6 compared to 1.31% in the parent 
UROtsa cell line. For the remaining isolates, less than 2% were positive for N-cadherin. 
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Figure 3.8 The As
3+
 isolate #6 has dramatically increased numbers of N-cadherin-
positive cells. Flow cytometry analysis for N-cadherin indicated by PE fluorescence in 
parent and As
3+ 
#6. Negative samples are no antibody controls. 
 
 
 
 
Table 3.1 As
3+ 
isolate #6 has the highest percentage of N-cadherin-positive cells. 
Table indicates number and percent of cells positive for low, medium, and high intensity 
PE-conjugated N-cadherin. Negative samples indicate no antibody controls. 
 
The fact that all isolates formed tumors lacking N-cadherin, independent of its 
expression in vitro, suggested that a unique subset of cells negative for N-cadherin 
existed within the cell population, and that this subset was responsible for tumor 
Isolate
Cells               
(Number)
Low                          
N-cadherin 
(Number)
Low                          
N-cadherin 
(Percent)
Moderate         
N-cadherin 
(Number)
Moderate           
N-cadherin 
(Percent)
High                       
N-cadherin 
(Number)
High                    
N-cadherin 
(Percent)
As #1 7896 6257 79.2 994 12.6 65 0.82
As #3 7317 3840 52.5 2982 40.8 117 1.6
As #6 7536 2 0.027 9 0.12 7426 98.5
Cd #1 7140 3325 46.6 3207 44.9 101 1.41
Cd #4 8072 5725 70.9 1736 21.5 77 0.95
Cd #5 6868 1866 27.2 4354 63.4 60 0.87
Parent 4437 1677 37.8 2583 58.2 58 1.31
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formation.  The potential for tumor-initiating cells, or cancer stem cells, was then 
investigated. Indeed, microspheres were derived from transformants by seeding at low 
density on low-adherence flasks, a typical protocol for initial cancer stem cell isolation. 
Further, the individual cells were able to regenerate microspheres following repeated 
dissociation, confirming their self-renewal capability. Upon IP injection into nude mice, 
the microspheres were also able to initiate tumor formation, further indicating their 
cancer stem cell-like characteristics. PCR analysis for cancer stem cell markers was 
performed, revealing that the microspheres expressed increased levels of ALDH1A1, 
though CD44 expression was reduced relative to the corresponding isolates (Figure 
3.9.A, B). Upon investigation of N-cadherin in the microspheres, mRNA levels were 
compared to their corresponding transformed isolates, indicating that this putative cancer 
stem cell population does not express N-cadherin (Figure 3.9.C). 
 
 
Figure 3.9 Microspheres originating from As
3+
- and Cd
2+
-transformed isolates 
express cancer stem cell marker ALDH1A1, but low levels of N-cadherin. A) Real 
time RT-PCR analysis of A) ALDH1A1 in parent UROtsa cells, As
3+
 and Cd 
2+
 
transformants and corresponding microspheres, B) CD44, and C) N-cadherin in parent 
UROtsa cells, As
3+
 and Cd 
2+
 transformants and corresponding microspheres expressed as 
fold change normalized to β-actin. PCR results represent Mean ±SEM of triplicate 
determinations. *p<0.05, **p<0.01, ***p<0.001 
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 The transcriptional regulation of N-cadherin is largely unknown. While a number 
of transcription factors have been implicated in various tissues, no studies are available 
on the regulation of N-cadherin in bladder cancer progression through EMT. To 
determine whether N-cadherin expression is a participant in cancer initiated specifically 
by As
3+
 or Cd
2+
, rather than a change occurring downstream of carcinogenesis, non-
malignant parent UROtsa cells were exposed to 1 µM CdCl2 or NaAsO2. Sodium arsenite 
failed to induce N-cadherin expression (Figure 3.10.A), while mRNA and protein levels 
were induced beginning at 15 days of cadmium exposure (Figure 3.10.B, C). 
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Figure 3.10 N-cadherin expression is induced in parent UROtsa cells exposed to     
1 µM CdCl2 over 30 days. A) Real time RT-PCR analysis of N-cadherin over 30 days 
exposure to 1 µM sodium arsenite expressed as fold change normalized to β-actin. B) 
Real time RT-PCR analysis of N-cadherin over 30 days exposure to 1 µM cadmium 
chloride expressed as fold change normalized to β-actin. C) Western blot analysis of N-
cadherin protein over 30 days exposure to 1 µM cadmium chloride. PCR results represent 
Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, ***p<0.001 
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Interestingly, the expression of N-cadherin is maintained in As
3+
- and Cd
2+
-
transformed cells after removal of the heavy metals, indicating that permanent changes in 
gene regulation have taken place. To determine whether epigenetic modifications may 
play a role in N-cadherin expression, parent UROtsa cells were treated with the histone 
deacetylase inhibitor MS-275 and the DNA methyltransferase inhibitor 5’-azacytidine (5-
AZC). Expression of N-cadherin mRNA was induced in a dose-dependent manner upon 
MS-275 exposure (Figure 3.11.A), whereas very little change was seen after exposure to 
5-AZC (Figure 3.11.B), indicating that histone acetylation state may regulate expression 
of N-cadherin in UROtsa cells.  
 
 
 
Figure 3.11 N-cadherin expression is altered by MS-275 exposure, while relatively 
unchanged following 5’-AZC. A) Real time RT-PCR analysis of N-cadherin following 
24 hr treatment with 0, 1, 3, and 10 µM MS-275. Expressed as fold change normalized to 
β-actin. B) Real time RT-PCR analysis of N-cadherin following 48 hr treatment with 0, 
0.5, 1, 1.5, and 3 µM 5’-AZC. Expressed as fold change normalized to β-actin. PCR 
results represent Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, 
***p<0.001 
 
To further investigate the role of histone modification on N-cadherin 
transcription, chromatin immunoprecipitation (ChIP) was performed for histone 4 total 
acetylation and histone 3 lysine 9 trimethylation at two regions within 2,000 bp upstream 
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of the N-cadherin transcription start site (Figure 3.12). Exposure to cadmium and arsenite 
did not alter H3K9Me3 at Region 1. In addition, MS-275 treatment did not change 
H3K9Me3 levels at this region (Figure 3.13). At Region 2, parent UROtsa cell exposure 
to sodium arsenite for five passages led to increased H4Ac levels (Figure 3.14). 
Cadmium chloride treatment induced H4Ac after 48 hrs, though the increased levels were 
not maintained long-term. However, treatment with histone deacetylase MS-275 
dramatically induced H4Ac in all treatment groups (Figure 3.14).  
 
Figure 3.12 Schematic illustration of the N-cadherin promoter. 
 
 
 
 
 
Figure 3.13 Histone 3 lysine 9 trimethylation is unchanged at Region 1 of the N-
cadherin promoter following MS-275, As
3+
, or Cd
2+
 exposure. A) Ethidium bromide-
stained gel showing amplification of H3K9Me3 using semiquantitative PCR. B) 
Quantified results of H3K9Me3 normalized to percentage of input. 
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Figure 3.14 Arsenite exposure and MS-275 increase total histone 4 acetylation at 
Region 2 of the N-cadherin promoter. A) Ethidium bromide-stained gel showing 
amplification of H4Ac using semiquantitative PCR. B) Quantified results of H4Ac 
normalized to percentage of input. P5 indicates exposure through five passages of cell 
culture.  
 
EMT Progression in As
3+
- and Cd
2+
-transformed UROtsa Cells 
 
 The levels of E-cadherin were determined both in vitro and in heterotransplants 
originating from As
3+
 and Cd
2+
 isolates. E-cadherin was unchanged at the mRNA level in 
both As
3+
- and Cd
2+
-transformed UROtsa cells (Figure 3.15.A), and no alterations were 
seen in protein as determined by Western blot analysis (Figure 3.15.B). 
Immunofluorescent staining for E-cadherin demonstrated localization of the protein at the 
cell membrane at regions of cell to cell contact. E-cadherin was consistently labeled in all 
isolates examined (Figure 3.16). Co-immunofluroescence for N-and E-cadherin indicated 
that N-cadherin did not replace E-cadherin localization at the membrane in any of the 
transformed isolates (Figures 3.17, 3.18). 
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Figure 3.15 E-cadherin is unchanged in As
3+
 and Cd
2+ 
transformants. A) Real time 
RT-PCR analysis of E-cadherin in parent UROtsa cell line and As
3+
 and Cd
2+
 isolates 
expressed as fold change normalized to β-actin. B) Western blot analysis of E-cadherin 
protein in As
3+
 and Cd
2+
 isolates. PCR results represent Mean ±SEM of triplicate 
determinations. 
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Figure 3.16 E-cadherin is consistently expressed at the cell membrane in As
3+
- and 
Cd
2+
-transformed UROtsa cells. A) Parent UROtsa cell line, B) As#3, C) As#6, D) 
Cd#1, E) Cd#4. Bar= 25 µM. 
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Figure 3.17 N-cadherin and E-cadherin are co-expressed at the cell membrane in 
As
3+
-transformed UROtsa cells. N-cadherin staining in A) parent UROtsa cell line, D) 
As#3, and G) As#6. E-cadherin staining in B) parent UROtsa cell line, E) As#3, and H) 
As#6. N-cadherin and E-cadherin co-immunofluorescence in C) parent UROtsa cell line, 
F) As#3, and I) As#6. 
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Figure 3.18 N-cadherin and E-cadherin are co-expressed at the cell membrane in 
Cd
2+
-transformed UROtsa cells. N-cadherin staining in A) parent UROtsa cell line, D) 
#1, and G) Cd#4. E-cadherin staining in B) parent UROtsa cell line, E) Cd#1, and H) 
Cd#4. N-cadherin and E-cadherin co-immunofluorescence in C) parent UROtsa cell line, 
F) Cd#1, and I) Cd#4. 
 
Investigation of E-cadherin in subcutaneous heterotransplant tumors yielded 
similar results, with no change observed in As
3+
 or Cd
2+
 tumors (Figure 3.19). While 
some induction was seen at the mRNA level in the As
3+
 isolates (Figure 3.19.A), a 
corresponding increase in E-cadherin protein was not found (Figure 3.19.B). Tumor 
immunohistochemistry showed SC tumors strongly positive at the plasma membrane for 
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E-cadherin in both As
3+
-
 
and Cd
2+
-derived tumors (Figures 3.20 and 3.21). Levels were 
similarly strong in the IP heterotransplant tumors (Figure 3.22). 
 
 
Figure 3.19 E-cadherin is unchanged in subcutaneous heterotransplants. A) Real 
time RT-PCR analysis of E-cadherin in parent UROtsa cells and SC tumors derived from 
As
3+
 and Cd
2+
 isolates expressed as fold change normalized to β-actin. B) Western blot 
analysis of E-cadherin protein in SC tumors originating from As
3+
 and Cd
2+
 isolates. PCR 
results represent Mean ±SEM of triplicate determinations. 
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Figure 3.20 Immunohistochemical analysis demonstrates strong E-cadherin staining 
in subcutaneous heterotransplant tumors derived from As
3+
- transformed isolates. 
E-cadherin is strongly positive in As
3+
  heterotransplant tumors. The staining is stronger 
in the peripheral cells than the cells in the center of tumor nests. Magnification 200X A) 
As#1, B) As#2, C) As#3, D) As#4, E) As#5, F) As#6. 
66 
 
 
Figure 3.21 Immunohistochemical analysis demonstrates strong E-cadherin staining 
in subcutaneous heterotransplant tumors derived from Cd
2+
- transformed isolates. 
E-cadherin is strongly positive in heterotransplant tumor formed from all Cd
2+
 isolates. 
The staining is stronger in the peripheral cells than the cells in the center of tumor nests. 
Magnification 200X. A) Cd#1, B) Cd#2, C) Cd#3, D) Cd#4, E) Cd#5, F) Cd#6, G) Cd#7. 
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Figure 3.22 E-cadherin is strongly positive in IP heterotransplant tumors. A) As#1, 
B) As#3, C) Cd#1. E-Cadherin is strongly positive in the tumor cells from all 3 IP 
tumors, with staining pattern similar to its subcutaneous counterparts. Magnification 
200X. 
 
 The levels of N-cadherin mRNA were then compared to the human bladder 
cancer cell lines J82 and TCCSUP, which have been previously characterized as 
mesenchymal, and the epithelial bladder cancer RT4 (Figure 3.23). The UROtsa isolates 
As#6 and Cd#5 highly expressing N-cadherin displayed levels of N-cadherin comparable 
to the cell lines J82 and TCCSUP. In fact, As#6 demonstrated higher N-cadherin 
expression than the human bladder cancer cell lines. However, RT-PCR with a different 
set of primers which detect all splice variants of N-cadherin found that the cell lines J82 
and TCCSUP contain higher levels of total N-cadherin mRNA in comparison to the 
UROtsa isolates As#6 and Cd#5 (Appendix, Figure 5.1), suggesting that the human 
bladder cancer cell lines utilize alternative splice variants to a greater extent. 
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Figure 3.23 N-cadherin mRNA is expressed in the transformed UROtsa isolates 
Cd#5 and As#6 at similar or higher levels than the mesenchymal-like bladder cancer 
cell lines J82 and TCCSUP. PCR analysis of N-cadherin expressed as fold change 
normalized to β-actin. PCR results represent Mean ±SEM of triplicate determinations. 
 
 To further characterize the EMT state of As
3+
- and Cd
2+
-transformed UROtsa 
cells, the expression of the pro-EMT transcription factors Twist, Snail, Slug, Zeb1, and 
Zeb2 were measured at the mRNA level in vitro. Expression of Twist was significantly 
increased five to 15-fold in both the As
3+
 and Cd
2+ 
isolates compared to parent UROtsa 
cells (Figure 3.24). Snail mRNA was significantly induced in As
3+
-transformed isolates 
relative to parent, with the exception of isolate #4, which was dramatically increased 
(Figure 3.25.A). Induction was also seen at a similar level in the Cd
2+
-transformed 
UROtsa cells (Figure 3.25B). 
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Figure 3.24 Twist expression is induced in As
3+
 and Cd
2+ 
isolates. A) Real time RT-
PCR analysis of Twist in parent UROtsa cells and A) As
3+
 isolates, and B) Cd
2+
 isolates 
expressed as fold change normalized to β-actin. PCR results represent Mean ±SEM of 
triplicate determinations. *p<0.05, **p<0.01, ***p<0.001 
 
 
Figure 3.25 Snail expression is induced in As
3+
 and Cd
2+ 
isolates. A) Real time RT-
PCR analysis of Twist in parent UROtsa cells and A) As
3+
 isolates and B) Cd
2+
 isolates 
expressed as fold change normalized to β-actin. PCR results represent Mean ±SEM of 
triplicate determinations. *p<0.05, **p<0.01, ***p<0.001 
 
 Immunohistochemistry was performed for Snail on heterotransplant tumors 
originating from the transformed isolates injected IP (Figure 3.26). The tumors deep 
within the abdominal cavity (retroperitoneum or around kidney) from all 3 mice showed 
moderate or moderate to strong staining of Snail (Figure 3.26.B, D, F), while the staining 
of Snail is weaker in the superficial tumor in peritoneum from the same mice (Figure 
3.26.A, C, E). Snail staining was strongest at the center of the tumor nests in the more 
differentiated cells, while weaker at the periphery. 
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Figure 3.26 Immunostaining for Snail is positive in IP tumors derived from As
3+
 and 
Cd
2+ 
isolates. As#1 tumor located A) at peritoneum, B) deep in abdominal cavity near 
kidney. As#3 tumor located C) at peritoneum, D) deep in abdominal cavity. Cd#1 tumor 
located E) at peritoneum, F) deep in abdominal cavity. The positive staining of Snail is 
mainly located in the center of the tumor nests, the cells that are relatively well 
differentiated with more cytoplasm. The less differentiated cells at the periphery are 
almost negative for Snail or only show very weak staining. Magnification 200X. 
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 Vimentin expression was then considered, as it is a common marker for 
mesenchymal cells. The majority of As
3+
 isolates showed unchanged levels of Vimentin 
mRNA, with the exception of a significant decrease in As#1, and significantly increased 
expression in As#5 (Figure 3.27.A). In Cd
2+
-transformed UROtsa cells, Vimentin was 
significantly reduced in most isolates (Figure 3.27.B). Analysis of the pro-EMT 
transcription factors Slug, Zeb1, and Zeb2 was also performed at the mRNA level, 
though no expression was detected. 
 Transcription factor 4 (TCF4), is an E2-2 protein recently associated with EMT 
(Sobrado et al., 2009). Interestingly, expression of TCF4 mRNA was significantly 
enhanced in most As
3+
 isolates about 10 to 50-fold compared to parent UROtsa 
cells(Figure 3.28.A). TCF4 was similarly induced in the Cd
2+
 transformants, to a slightly 
lesser extent (Figure 3.28.B). 
 
Figure 3.27 Vimentin expression is unaltered in As
3+
-transformed UROtsa cells, 
while induced in Cd
2+ 
isolates. A) Real time RT-PCR analysis of Vimentin in parent 
UROtsa cells and As
3+
 isolates expressed as fold change normalized to β-actin. B) Real 
time RT-PCR analysis of Vimentin in parent UROtsa cells and Cd
2+
 isolates expressed as 
fold change normalized to β-actin. PCR results represent Mean ±SEM of triplicate 
determinations. *p<0.05, **p<0.01, ***p<0.001 
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Figure 3.28 TCF4 expression is induced in As
3+
 and Cd
2+ 
isolates. A) Real time RT-
PCR analysis of TCF-4 in parent UROtsa cells and As
3+
 isolates expressed as fold change 
normalized to β-actin. B) Real time RT-PCR analysis of TCF-4 in parent UROtsa cells 
and Cd
2+
 isolates expressed as fold change normalized to β-actin. PCR results represent 
Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, ***p<0.001 
 
 Other EMT-associated genes were evaluated at the mRNA level. STEAP1, or six 
transmembrane epithelial antigen of the prostate 1, expression was induced in Cd
2+
-
transformed UROtsa cells in vitro and in a number of SC tumors (Figure 3.29.B and D). 
STEAP1 was less consistently induced in the As
3+
 transformants, though it was elevated 
in a number of isolates in vitro and in vivo (Figure 3.29.A and C). STEAP1 is considered 
to increase during EMT, though further experimental evidence is required to confirm its 
role in EMT.  Occludin (OCLN), a component of tight junctions, is typically decreased 
during EMT (Ikenouchi, Matsuda, Furuse, & Tsukita, 2003). However, in As
3+
- and 
Cd
2+
-transformed UROtsa cells, occludin was increased in many isolates in vitro and in 
SC tumors (Figure 3.30). Interleukin 1 receptor antagonist, or IL1RN, is another gene 
downregulated during EMT, though its expression was unchanged in As
3+
-transformed 
UROtsa cells and significantly decreased in Cd
2+
 transformants (Figure 3.31). 
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Figure 3.29 STEAP1 is consistently induced in Cd
2+
-transformed UROtsa cells in 
vitro and maintained in some subcutaneous tumors. Real time RT-PCR analysis 
expressed as fold change over parent normalized to β-actin in A) As3+-transformed 
UROtsa cells, B) Cd
2+
-transformed UROtsa cells, C) SC tumors derived from As
3+
 
transformants and D) SC tumors derived from Cd
2+
 transformants. Results represent 
Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, ***p<0.001 
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Figure 3.30 OCLN is consistently induced in Cd
2+
-transformed UROtsa cells in vitro 
and maintained in select subcutaneous tumors. Real time RT-PCR analysis expressed 
as fold change over parent normalized to B-actin in A) As
3+
-transformed UROtsa , B) 
Cd
2+
-transformed UROtsa cells, C) SC tumors derived from As
3+
 transformants and D) 
SC tumors derived from Cd
2+
 transformants. Results represent Mean ±SEM of triplicate 
determinations. *p<0.05, **p<0.01, ***p<0.001 
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Figure 3.31 IL1RN is varied in Cd
2+
-transformed UROtsa cells in vitro and in vivo. 
Real time RT-PCR analysis expressed as fold change over parent normalized to B-actin 
in A) As
3+
-transformed UROtsa cells, B) Cd
2+
-transformed UROtsa cells, C) SC tumors 
derived from As
3+
 transformants and D) SC tumors derived from Cd
2+
 transformants. 
Results represent Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, 
***p<0.001 
#
 indicates significantly induced 
#
p<0.05, 
##
p<0.01, 
###
p<0.001.
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CHAPTER IV 
DISCUSSION 
Model Systems of Bladder Cancer in vivo 
 The fact that N-cadherin expression is maintained in IP, but not SC 
heterotransplants suggests that tumor microenvironment may play a role in regulation of 
N-cadherin and in tumor development in general. While expression of N-cadherin is 
highly induced in vitro in As
3+
- and Cd
2+
-transformed UROtsa cells, the cell lines may 
not have maintained their molecular characteristics upon subcutaneous injection due to 
the lack of a supportive environment for progression through EMT. When injected IP, 
however, the environment more closely replicates that of bladder cancer cells progressing 
through EMT and metastasis, which promotes the maintenance of N-cadherin expression 
in transformed UROtsa cells. Animal models for bladder cancer are scarce in comparison 
to those of other cancers (Kobayashi, Owczarek, McKiernan, & Abate-Shen, 2015).  
The compatibility of in vitro and animal models is an issue that is overlooked in a 
number of cancers. Subcutaneous xenografts are a popular system due to the ease of cell 
transplant and observation of tumor formation and growth. However, numerous clinical 
trials for cancer therapeutics based on testing in SC tumor models have proven 
unsuccessful (Suggitt & Bibby, 2005). In a study of colon cancer, subcutaneous tumors 
demonstrate sensitivity to doxorubicin, while lung metastases developed by tail vein 
injection of cancer cells are resistant. Further, expression of the genes MDR1 and p-
glycoprotein is enhanced in the resistant metastases compared to the subcutaneous tumors 
(Dong et al., 1994). Human tumor xenografts of ovarian carcinoma also display site-
specific sensitivity to the anti-cancer drug flavone acetic acid. Intraperitoneal tumors fail 
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to respond to treatment, while subcutaneous tumors show growth inhibition (Pratesi, 
Manzotti, Tortoreto, Audisio, & Zunino, 1991). Interestingly, the majority of studies 
involving tumor heterotransplants only observe the effects of drug treatment on tumor 
formation and growth, and do not investigate whether the compounds targeted by the 
drug in in vitro studies are present or altered in the animal model. Further, while some 
studies compare xenograft and original tumor histology and general appearance, 
molecular characterization rarely occurs. The xenograft lines UCRU-BL-12 and UCRU-
BL-14 are an example in which the original SC tumors were histologically similar, but 
following serial implantations, differing DNA profiles developed with the emergence of 
aneuploid populations (Russell et al., 1986). In an orthotopic model of bladder cancer, 
expression of various integrins and MMPs is altered compared to in vitro levels in RT4 
cells (Imao et al., 1999). Proper pairing between in vitro cell lines and animal models 
may result in higher success rates at clinical trials and the development of biomarkers of 
better predictive value for a number of cancers in addition to bladder cancer. 
Some success has been found in other heterotransplant models. While 
subcutaneous injection of cancer cells encapsulates the tumor and reduces the potential 
for metastasis (Ahlering, Dubeau, & Jones, 1987; Kubota, 1994), injection of cells into 
the peritoneum is considered to more closely replicate the environment into which 
bladder, prostate, ovarian, and gastric cancers initially metastasize (Garson, Shaw, Clark, 
Yao, & Vanderhyden, 2005). In fact, the bladder cancer cell line RT4 and endometrial 
carcinoma line EJ shows little metastatic potential when transplanted subcutaneously. 
However, when the same lines are injected via tail vein, metastatic sites develop. When 
injected orthotopically to the bladder lumen, the cells develop tumors similar in histology 
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and behavior to their tumors of origin (C. Zhang, Awasthi, Schwarz, & Schwarz, 2013). 
The development of a renal capsule model of bladder cancer using As
3+
- and Cd
2+
-
transformed UROtsa cells is currently in development.  
Bladder Cancer Stem Cells 
 Heterogeneity among cells within the transformed isolates may also contribute to 
dissimilar N-cadherin expression in tumor heterotransplants versus in vitro cultures. The 
UROtsa cell line and its transformants are not clonal populations. During transformation 
with sodium arsenite and cadmium chloride, the cells experienced numerous phases of 
massive cell death followed by regrowth from surviving cells, in which the surviving 
clones were not isolated for clonal expansion. Examination of cellular heterogeneity 
within each isolate had not been performed previously.  
To quantitatively determine the number of cells positive for N-cadherin, flow 
cytometry was performed on As
3+
 and Cd
2+
 isolates expressing low, medium, and high N-
cadherin as indicated by Western blot. Results of the flow cytometry experiments found 
that N-cadherin was only detected on the highest expressing isolate, As#6, and that 
98.5% of the cells were positive for the protein. This is contrary to the findings from 
Western blot analysis, suggesting that the levels initially observed included both 
intracellular and membrane-bound N-cadherin, while the flow cytometry only detected 
membrane-bound protein. Additionally, Western blot analysis with the antibody used for 
flow cytometry demonstrated lower sensitivity, indicating that antibody did not detect the 
N-cadherin on the the moderately-expressing isolates As#3 and Cd#1.    
To further investigate the hypothesis that population heterogeneity was at play in 
the As
3+
- and Cd
2+
-transformed UROtsa, the presence of tumor-initiating cells, or cancer 
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stem cells, was investigated were identified within As
3+
- and Cd
2+
-transformed UROtsa 
cells, suggesting that a unique subpopulation of cells in vitro are responsible for tumor 
formation in vivo which may then display different molecular characterization than 
observed in culture. 
Microspheres were isolated by cell culture in serum-free media at low density on 
low-adherence substrates. Following microsphere, or urosphere, formation, self-renewal 
was confirmed by the ability to reform colonies following multiple rounds of dissociation 
(data not shown). The microspheres were able to form tumors following IP injection into 
nude mice, further validating their stem cell-like characteristics (data not shown). 
Interestingly, the putative stem cells display significantly reduced N-cadherin 
expression compared to their counterparts grown in serum-free media as evaluated by 
RT-PCR, even in As
3+
 isolate #6, which shows the most dramatic increase in N-cadherin 
compared to the parent UROtsa cell line, with 98.5% of cells positive for N-cadherin by 
flow cytometry analysis. This suggests that a small subset of N-cadherin-negative cells 
act as tumor-initiating cells to develop tumors in vivo, resulting in the lack of N-cadherin 
expression observed. 
 Bladder cancer stem cells were first isolated as side populations from primary 
cultures of low-grade papillary urothelial carcinoma. Side population (SP) is defined by 
the ability to efflux the DNA-binding dye Hoescht 33342, and has been further 
characterized as a functional marker for stem cells in numerous normal and cancerous 
tissues. Another marker for bladder cancer stem cells is EMA
-
CD44v6
+
, which was 
initially identified in primary cultures of low-grade papillary carcinoma. This cell 
population possesses the ability for anchorage-independent colony formation, self-
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renewal, and proliferation in vitro (Y. M. Yang & Chang, 2008). Cancer stem cells 
demonstrate an enhanced ability to form tumors in vivo that replicate the original tumor. 
In a study by Chan et al., CD44
+
 cells isolated from patient tumors display increased 
ability to form tumors following SC injection into nude mice compared to CD44
-
 cancer 
cells. Further, the CD44
+
 cells are able to be serially transplanted for three additional 
passages (Chan et al., 2009).  
Cancer stem cells have been isolated from immortalized bladder cancer lines, as 
well. Side populations were identified in the bladder cancer cell lines SW780, UM-UC-6, 
UM-UC-6dox, 253J-BV, and HT-1197 (Jun, Peng, Zi, Wei, & Xiang, 2008). The cells 
demonstrate higher colony-forming efficiency in soft agar than non-SP cells, as well as 
tumor formation in subcutaneous xenografts. Expression of the ABC transporters 
ABCG2 and MDR1 is significantly increased in SP cells, supporting their enhanced 
efflux capability. Further, the stem cell genes Oct-4 and Bmi-1 are also elevated in the SP 
cells. Stem-like cells have also been identified in SP cells from the transitional cell 
carcinoma cell line T24. The side populations display increased cell growth and elevated 
expression of ABCG2 expression, a marker of stem cells (Ning et al., 2009). Stem cell-
like compartments have been identified in heterotransplant models of bladder cancer. 
Human SW780 urothelial carcinoma xenografts derived from high-grade invasive 
carcinoma demonstrate basal-like CK17
+
 staining in cells at the tumor-stroma interface 
and CK20 expression within the interior of tumor nodules which resembles staining seen 
in superficial cells of the normal urothelium (X. He et al., 2009).  
Aldehyde dehydrogenase 1 expression has also emerged as a marker for bladder 
cancer stem cells. ALDH1A1
+
 cells isolated from the bladder cancer cell lines RT4, 
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HTB-9, and HTB-4 display significantly higher colony forming efficiency which is 
reversed upon ALDH1A1 knockdown. Further, anchorage-independent growth is 
impaired in cells with reduced ALDH1A1. ALDH1A1
+
 cells demonstrat increased in vivo 
tumorigenicity when compared with ALDH1A1
-
 cells, and the tumors are able to be 
regenerated for at least three cycles. In human bladder cancer specimens, ALDH1A1 is 
not observed in normal urothelium, though it is colocalized with tumor cells positive for 
the stem cell marker CD44. In addition, ALDH1A1 status is significantly correlated with 
grade and stage of bladder carcinoma, incidence of recurrence, progression, and inversely 
associated with survival (Y. Su et al., 2010). 
There is no consensus on bladder cancer stem cell markers (van der Horst, Bos, & 
van der Pluijm, 2012). Other stem cell markers that have been utilized include VEGFR2, 
CD133, Sox2, Nanog, and 67LR (Goodwin Jinesh, Willis, & Kamat, 2014; van der Horst 
et al., 2012). For the purpose of identifying stem cell-like populations with the UROtsa 
cell line and its transformants, the markers ALDH1A1 and CD44 were used. RT-PCR 
analysis demonstrated increased expression of ALDH1A1 mRNA, though not CD44 in 
urospheres compared to the transformants grown in serum-free media. 
In light of the theory that N-cadherin-negative stem cells are forming 
subcutaneous tumors lacking N-cadherin expression, why might these same cells create 
tumors in the peritoneum that regain N-cadherin? Once again, tumor microenvironment 
appears to play a role. In small cell lung cancer, tumor specimens serially propagated in 
vivo lose expression of tumor-specific genes when transitioned to cell culture conditions. 
This change in gene expression is not reversed upon regraftment into mice, implicating 
permanent changes in cell phenotype dependent upon tumor environment (Daniel et al., 
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2009). The progression of cells through EMT to metastasis specifically is also regulated 
by environment (Polyak & Weinberg, 2009). A study inducing EMT in hamster cheek 
pouch carcinoma-1 cells by TGF-β found that both mesenchymal-like and epithelial-like 
cells establish tumors upon subcutaneous injection. Only cells induced to undergo EMT 
invade adjacent tissue, and neither cell type metastasizes to the lung. However, upon 
intravenous injection only the epithelial cells develop lung metastases. Subcutaneous 
injection of a mixture of both epithelial and EMT-induced cells allows invasion and lung 
metastasis of epithelial cells (T. Tsuji et al., 2008). In another study utilizing prostate and 
bladder cancer cell lines, tumor-initiating cells demonstrating epithelial characteristics are 
able to metastasize and colonize distant sites, while cells with a mesenchymal phenotype 
do not have this ability. Instead, the mesenchymal-like tumor-initiating cells show 
enhanced local invasiveness when compared to the epithelial cells (Celià-Terrassa et al., 
2012). This suggests that the tumor microenvironment plays a role in cancer progression 
to metastasis, and that both epithelial and mesenchymal stem cells promote cancer 
progression (Polyak & Weinberg, 2009). Lastly, cancer stem cells in particular are 
dependent upon their surrounding conditions for maintenance of the tumor-initiating 
phenotype. Heterogeneity has been identified in stem-like populations isolated from 
human bladder transitional cell carcinoma. These cells are positive for the stem cell 
markers CD133, Oct-3/4, and nestin, and display increased proliferation and self-renewal. 
However, upon continued culture the cells gradually loset their proliferative and 
morphological characteristics and are unable to induce xenograft tumors in vivo 
(Bentivegna et al., 2010). These studies suggest that N-cadherin expression in tumor 
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heterotransplants requires an environment supportive of EMT, and that tumor stem cells 
are also vulnerable to changes in microenvironment.  
The origins of cancer stem cells remain unclear. They may arise from normal 
stem or progenitor cells (Feng Li, Tiede, Massagué, & Kang, 2007), or may be derived 
from differentiated cells that undergo a series of oncogenic hits to acquire self-renewal 
ability and immortality (Clarke et al., 2006). However, numerous studies have found that 
heavy metals can cause normal stem cells to develop a cancer stem cell-like phenotype. 
Normal stem cells from human prostate acquire cancer stem cell-like characteristics when 
co-cultured with transformed malignant epithelial cells. However, the phenotype is only 
adapted when stem cells are cultured with arsenic-transformed, but not N-methyl-N-
nitrosourea-transformed epithelial cells (Yuanyuan Xu et al., 2013). In human 
keratinocyte HaCaT cells, transformation by low dose exposure to sodium arsenite 
occurrs via EMT, followed by the acquisition of a malignant cancer stem cell-like 
phenotype (R. Jiang et al., 2013). Human pancreatic ductal epithelial cells exposed to 
chronic cadmium induce non-adherent spheroid formation and expression of the stem cell 
markers OCT4 and CD44, as well as a cancer phenotype indicated by enhanced invasion 
and expression of the pancreatic cancer marker S100P (Qu, Tokar, Kim, Bell, & 
Waalkes, 2012). Arsenic induces EMT and malignant transformation in human bronchial 
epithelial cells, as well as cancer stem cell-like characteristics, which are directly 
regulated by HIF-2α (Yuan Xu et al., 2012). 
Human prostate stem cells show enhanced resistance to arsenite-induced 
cytotoxicity compared to the mature parental cell line, and possess hyper-adaptability to 
arsenic. Further, experiments by Tokar et al. indicate that exposure to arsenic induces 
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greater numbers of free-floating spheres in the parental prostate cell line than cadmium or 
N-methyl-N-nitrosourea (Tokar, Qu, et al., 2010). Additional studies prove that arsenite 
exposure transforms normal prostate stem cells to a malignant cancer stem cell-like 
phenotype with high invasion capacity and loss of contact inhibition. The cells are also 
able to form tumors when heterotransplanted that were highly aggressive, containing 
immature epithelial- and mesenchymal-like cells (Tokar, Diwan, & Waalkes, 2010). As 
previously mentioned, during As
3+
- and Cd
2+
-induced transformation in UROtsa cells, a 
small percentage of cells survived numerous rounds of cytotoxicity. It would prove quite 
interesting to isolate those cells and determine whether they contain cancer stem cell 
markers, as well as the changes that occur with each round of toxicity.  
Future experiments using flow cytometry to determine the expression of cancer 
stem cells including ALDH1A1, CD44, and CD133 will be necessary to establish that the 
microspheres indeed contain cancer stem cells. Additional studies to determine the 
expression E-cadherin and N-cadherin in the cancer stem cell population are also 
required, as it may be that an epithelial tumor-initiating cell population establishes IP 
tumors, while an N-cadherin-expressing population develops tumors subcutaneously.  
In order to address the role of microenvironment on N-cadherin expression, the 
renal capsule model will be utilized. Grafting cells in the renal capsule is more efficient 
than subcutaneous injections and has good predictive value of clinical response 
(Baiocchi, Biffoni, Ricci-Vitiani, Pilozzi, & De Maria, 2010; Suggitt & Bibby, 2005). 
Further, normal urothelial cells injected into the renal capsule are able to establish and 
grow, providing an in vivo control for comparison with tumors derived from As
3+
- and 
Cd
2+
-transformed UROtsa cells (Oottamasathien et al., 2006). 
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Characterization of EMT in UROtsa Transformants 
 Since N-cadherin induction is a common sign of the epithelial-to-mesenchymal 
transition, the As
3+
- and Cd
2+
-transformed UROtsa cells where characterized for 
additional markers of EMT. No changes in E-cadherin were seen at the mRNA or protein 
level in the transformed UROtsa cells. Further, E-cadherin did not appear to replace N-
cadherin at the plasma membrane, but instead was co-expressed. While E-cadherin is 
typically replaced by N-cadherin during EMT in the bladder, there are cases in which N- 
and E-cadherin are co-expressed, and that when this occurs, the functional properties of 
N-cadherin dominate over E-cadherin. In a study by Rieger-Christ and colleagues of a 
panel of bladder cancer cell lines, bladder cancers expressing high levels of E-cadherin 
with no N-cadherin display little invasive capacity, and those with high N-cadherin and 
reduced E-cadherin demonstrate high levels of invasiveness. Interestingly, when N- and 
E-cadherin are co-expressed, invasive capacity is elevated in comparison with N-
cadherin-negative cell lines, though not to the extent of cell lines with high N-cadherin 
and low E-cadherin (Kimberly M Rieger-Christ et al., 2004). This implies that the pro-
migratory property of N-cadherin overcomes the pro-epithelial effects of E-cadherin 
when co-expressed, allowing EMT progression with enhanced motility and invasion. This 
has also been observed in breast cancer, in which exogenous induction of N-cadherin in 
the MCF-7 cell line induces higher migration rates and increased invasion in Matrigel. 
When injected into nude mice, the cells co-expressing N- and E-cadherin are able to form 
metastatic tumors expressing both cadherins (Hazan, Phillips, Qiao, Norton, & Aaronson, 
2000). 
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The pattern of progression through EMT, that is, the timing of various markers 
and changes in behavior, has not been well-characterized in cancer. It is often dependent 
upon the cell type observed and the agent inducing the transition. N-cadherin induction 
has been correlated with tumor invasiveness, suggesting that it is upregulated late in 
EMT. When compared to the epithelial human bladder cancer cell line RT4, N-cadherin 
induction in As
3+
- and Cd
2+
-transformed UROtsa cells was elevated. However, the level 
of induction relative to mesenchymal bladder cancers J82 and TCCSUP depended upon 
the inclusion of N-cadherin splice variants, in which the human bladder cancer cell lines 
appear to utilize alternative splicing. Analysis of protein expression will ultimately 
determine whether N-cadherin levels in the UROtsa transformants are indeed at the 
extent of that seen in J82 and TCCSUP. Elevated Vimentin expression is often associated 
with late stage EMT; however in the UROtsa transformants it was not induced. Further, 
transformed UROtsa cells maintained an epithelial appearance (Sens et al., 2004). 
Interestingly, whereas N-cadherin demonstrates an important role for cell motility in a 
study of TGF-β1-induced EMT in mammary epithelial cells, it does not affect the 
morphological changes that accompany EMT. siRNA-mediated inhibition of N-cadherin 
expression does not alter cell morphology, while motility is decreased, as seen in wound-
healing and transwell motility assays (M. Maeda, Johnson, & Wheelock, 2005). 
However, in the case of As
3+
- and Cd
2+
 transformed UROtsa cells, only a few isolates 
demonstrate increased migration which do not correlate to N-cadherin expression and the 
transformed cells do not have increased invasive ability (J Larson, 2012). This suggests 
that while N-cadherin, Twist, and Snail are significantly elevated in transformed UROtsa 
cells, the cells are in the initial states of EMT. There are no models of this type for 
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bladder cancer, suggesting that the As
3+
- and Cd
2+
-transformed UROtsa cells will be of 
benefit for further characterization of the patterns of gene expression and behavioral 
changes in bladder cancer-associated EMT. While arsenite exposure did not induce N-
cadherin expression in parent UROtsa cells, expression was elevated with increased 
duration of cadmium exposure, providing a model system for the progression of EMT in 
bladder. Future experiments could include analysis of other EMT markers throughout this 
exposure period. The miR-200 family should also be explored in this system, as its 
expression has been associated with early stages of EMT in bladder cancer.  
 Other markers of EMT were investigated in As
3+
- and Cd
2+
-transformed UROtsa 
cells at the mRNA level, as well. The pro-mesenchymal transcription factor Twist was 
significantly induced in both As
3+
 and Cd
2+
 transformants. Interestingly, phosphorylated 
Twist activates transcription of TGF-β2 (Xue et al., 2012), an EMT-inducer that was 
upregulated on the As
3+
 array and to a lesser extent on the microarray for Cd
2+
 
transformants (Gao, Zhu, Nilsson, & Sundfeldt, 2014; Garrett et al., 2014; Medici, Hay, 
& Olsen, 2008). Snail, another transcription factor promoting EMT, was also 
significantly elevated. Vimentin expression was mostly unchanged in As
3+
-transformants, 
though reduced in the majority of Cd
2+
 isolates. Transcription factor 4, or TCF4, was 
significantly induced in As
3+
- and Cd
2+
-transformed UROtsa cells. This class 1 bHLH 
factor E2-2 protein is not to be confused with T-cell-specific transcription factor 4 
(TCF7L2), a factor associated with the Wnt signaling pathway. This transcription factor 
is relatively unexplored in EMT, though studies have proven that it is a potent inducer of 
EMT in MDCK cells (Sobrado et al., 2009). Additional transcription factors Zeb1 and 
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Zeb2 were measured, though expression was undetectable or unchanged (data not 
shown).  
 Other genes associated with EMT that were investigated included STEAP1, 
OCLN, and IL1RN. STEAP1, or six-transmembrane epithelial antigen of the prostate 1, 
is normally expressed at the membrane in low levels in bladder, but it is significantly 
upregulated in a number of bladder cancer cell lines, including UM-UC03, TCCSUP, and 
J82 (Hubert et al., 1999). In Cd
2+
-transformed UROtsa cells, STEAP1 was significantly 
induced in vitro, and numerous isolates demonstrated elevated expression in SC tumors. 
STEAP1 was less consistently induced in As
3+
 transformants in vitro and in vivo.  
STEAP1 appears to play a role in tumor growth and intercellular communication, as 
knockdown in prostate cancer and oral squamous cell carcinoma xenografts significantly 
reduces tumor volume and inhibited intercellular communication in vitro (T. Yamamoto 
et al., 2013). Further study of STEAP1 expression in bladder cancer is needed, as meta-
analysis of gene expression data from 40 human tumor types revealed that STEAP1 is 
significantly induced in 11 cancers, but bladder cancer is not one of them (Moreaux, 
Kassambara, Hose, & Klein, 2012). STEAP1 is induced during progression through 
EMT, though further evidence is required to confirm this association. 
 Occludin downregulation is observed in the epithelial-to-mesenchymal transition. 
Occludin is an integral membrane protein localized at tight junctions. In a Snail-induced 
model of EMT in mouse epithelial cells, Snail directly regulates occludin to decrease its 
expression (Ikenouchi et al., 2003). However, occludin was not reduced in As
3+
 and Cd
2+
 
transformants. In fact, expression was significantly upregulated in Cd
2+
-transformed 
UROtsa cells in vitro, and numerous SC tumors overexpressed occludin. Evaluation of 
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occludin expression at the protein level, as well as other tight junction proteins, may 
indicate whether loss of tight junction functionality is occurring in this bladder cancer 
model. 
 Interleukin 1 receptor antagonist (IL1RN) is also considered to decrease during 
EMT, though evidence is limited. In Cd
2+
-transformed UROtsa cells, IL1RN expression 
was significantly reduced, though results were varied in SC tumors. In As
3+
-
transformants, IL1RN was relatively unchanged. Interestingly, IL1RN gene 
polymorphism is associated with increased risk of bladder cancer (Ahirwar, Agrahari, 
Mandhani, & Mittal, 2009; Bid, Manchanda, & Mittal, 2006; Bozdoğan et al., 2014). 
Further, reduced IL1RN expression is significantly correlated with aggressive bladder 
cancer (Worst et al., 2014). 
Other groups have determined the EMT state of numerous bladder cancer cell 
lines. The TCCSUP, RT4, and J82 cell lines have been reviewed here (Table 4.1). The 
J82 cell line, also known as HTB-1, is derived from a poorly differentiated invasive 
transitional cell carcinoma of Stage T3 (O’Toole, Price, Ohnuki, & Unsgaard, 1978). It is 
the most mesenchymal of the three lines, with strong N-cadherin expression, low levels 
of E-cadherin, induced Vimentin and increased levels of the transcription factors Twist, 
Snail, Slug, Zeb1, and Zeb2. TCCSUP, or HTB-5, originates from Stage 4 transitional 
cell carcinoma and also contains mesenchymal characteristics with increased N-cadherin 
and pro-mesenchymal transcription factors, but without loss of E-cadherin, and does not 
display elevated Vimentin. RT4, or HTB-2, is the most epithelial of the three cell lines, 
and was derived from transitional cell papilloma. The cell line shows little induction of 
N-cadherin, strong E-cadherin, no Vimentin expression, and varied levels of pro-
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mesenchymal transcription factors (Baumgart et al., 2007). While further experiments are 
required to fully compare the As
3+
- and Cd
2+
-transformed UROtsa cells to these cell 
lines, they appear to be most similar to the TCCSUP cell line. Differences include the 
expression of Zeb1, Zeb2, Slug, and P-cadherin. Zeb1, Zeb2, and Slug were expressed at 
barely detectable levels which were unchanged in the As
3+
- and Cd
2+
-transformed 
UROtsa cells (data not shown). P-cadherin was expressed, through changes in expression 
were variable in the transformed cells (Appendix 5.1). 
By characterizing the early and late events of EMT in bladder tumors, biomarkers 
may be discovered which could earlier predict cancers with metastatic potential. It may 
be that As
3+
- and Cd
2+
-induced EMT utilizes a different pathway to induce EMT, or that 
TCCSUP represent a later stage. Analysis of human bladder cancer tumors from arsenic-
endemic regions may further establish the role of N-cadherin as a marker specific for 
heavy metal-induced bladder carcinogenesis and the initial stages of EMT. 
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  TCCSUP RT4 J82 UROtsa 
As
3+
 
UROtsa 
Cd
2+
 
UROtsa Reference 
N-cadherin       - + + Sandquist et al. 2015 
  ++ -       
 
Hänze et al. 2013 
    ++ +     
 
Hao et al. 2012 
  ++   +++     
 
Wallerand et al. 2010 
    - ++     
 
Sayan et al. 2009 
    - +++     
 
Wu et al. 2013 
  +++ - +++       Baumgart et al. 2007 
E-cadherin       + + + Sandquist et al. 2015 
  - +++       
 
Hänze et al. 2013 
      +     
 
Yang et al. 2014 
    +++ +     
 
Cheng et al. 2013 
  +++   -     
 
Wallerand et al. 2010 
    +++ +     
 
Hao et al. 2012 
  ++ +++ +     
 
Tran et al. 2012 
    +++ -     
 
Sayan et al. 2009 
    ++       
 
Choi et al. 2012 
    +++ -     
 
Wu et al. 2013 
  - +++ -       Baumgart et al. 2007 
Vimentin       + + - Sandquist et al. 2015 
  - -       
 
Hänze et al. 2013 
    + +++     
 
Cheng et al. 2013 
    -       
 
Choi et al. 2012 
    - ++     
 
Wu et al. 2013 
      +++     
 
Yang et al. 2014 
  - - +++     
 
Baumgart et al. 2007 
Snail       + ++ ++ Sandquist et al. 2015 
      ++     
 
Yang et al. 2014 
  ++ - -     
 
Matsui et al. 2012 
Zeb1       - - - Sandquist et al. 2015 
    -       
 
Cheng et al. 2013 
  +++ + +++     
 
Tran et al. 2012 
    - +++     
 
Sayan et al. 2009 
      +     
 
Yang et al. 2014 
    -         Choi et al. 2012 
Zeb2       - - - Sandquist et al. 2015 
  +++ + +++     
 
Tran et al. 2012 
    + +     
 
Sayan et al. 2009 
    -       
 
Choi et al. 2012 
Twist       + ++ ++ Sandquist et al. 2015 
      +++     
 
Yang et al. 2014 
    +       
 
Zhang et al. 2007 
  +++         
 
Shiota et al. 2010 
Slug - - -       Sandquist et al. 2015 
    + +     
 
Cheng et al. 2013 
  ++ ++ +     
 
Matsui et al. 2012 
    + +++     
 
Wu et al. 2013 
P-cadherin       + + + Sandquist et al. 2015 
  + +       
 
Mialhe et al. 2000 
    + -       Sayan et al. 2009 
Table 4.1 EMT characterization of transformed UROtsa cells with the human 
bladder cancer cell lines TCCSUP, RT4, and J82. +++ high, ++ moderate, + low, and 
– no expression. 
92 
 
Regulation of N-cadherin 
 While the importance of N-cadherin in the epithelial-to-mesenchymal transition 
has been well established, its regulation is relatively unknown. The transcription factor 
Twist regulate N-cadherin promoter activity by binding at an E-box within the first intron 
in prostate cancer cells (Alexander et al., 2006). Further, Twist was a top induced gene in 
As
3+
-transformed UROtsa cells and significantly upregulated in Cd
2+
-transformed 
isolates as indicated by microarray analysis (Garrett et al., 2014). Twist is a well-known 
repressor of E-cadherin that participates in EMT; therefore, dual functionality of Twist as 
both a repressor and inducer of E-cadherin and N-cadherin, respectively, is an attractive 
possibility that should be explored in a wider variety of cancers. 
 The potential regulation of Twist by arsenite exposure has not been fully studied. 
In human bronchial epithelial cells transformed by arsenite, the exposure inducs EMT, 
including the expression of Twist. Further, Twist upregulation is increased in 
nonmalignant cells depending upon duration of arsenite exposure, indicating metal-
dependent expression. However, cancer cells treated with arsenite show a different 
response. Arsenic trioxide is an effective treatment for some cancers, including 
hepatocellular carcinoma. In this cancer, arsenic trioxide reduces cell migration and 
invasiveness and inhibits EMT by suppressing Twist (G. Z. Wang et al., 2014). In non-
small-cell lung cancer, arsenic trioxide-induced cell death is enhanced by inhibition of 
Twist (Seo et al., 2014). As such, further studies are needed to explore the divergent 
mechanisms of Twist regulation by arsenite in normal and cancerous cell types. There is 
less evidence for regulation of Twist by cadmium exposure. In cadmium-treated mice, 
fibrotic kidney EMT is induced, accompanied by elevated Twist expression (Chakraborty 
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et al., 2010). It would also be worthwhile to investigate whether Twist is regulating N-
cadherin in As
3+
- and Cd
2+
-transformed UROtsa cells, considering the fact that E-
cadherin expression was unaltered by heavy metal transformation. It may be the case that 
Twist is acting solely as an inducer of N-cadherin expression, or that other regulatory 
factors are at play. 
 N-cadherin expression was altered by treatment with the histone deacetylase 
inhibitor MS-275, suggesting that acetylation contributes to the regulation of N-cadherin 
transcription. Exposure to sodium arsenite over 5 passages in the parent UROtsa cell line 
appeared to induce total levels of histone 4 acetylation at Region 2 of the N-cadherin 
promoter. Further, histone acetylation state was modified at Region 2 following exposure 
to MS-275, indicating that this may be a region of regulatory activity for N-cadherin 
transcription. However, numerous studies have indicated that arsenic reduces histone 
acetylation globally. Chu et al. found that exposure to arsenic reduces global histone 
acetylation (Chu et al., 2011) and another demonstrated that As(III) and MMA(III) 
reduce H4K16 acetylation in a time- and dose-dependent manner (Ge et al., 2013; Jo et 
al., 2009). Experiments with UROtsa cells exposed to longer durations of sodium arsenite 
and in transformed cells will confirm whether the increase in H4 acetylation at the N-
cadherin promoter is a gene-specific change, or if longer exposures to arsenic are needed 
to elevate histone acetylation at this region. 
 This work has demonstrated that N-cadherin is induced in As
3+
- and Cd
2+
-
transformed UROtsa cells, and that a unique early EMT signature may have potential to 
act as a biomarker of bladder cancer induced by arsenic and cadmium. These studies 
revealed important findings on the transcriptional regulation of N-cadherin, as well as 
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histone acetylation at the promoter. N-cadherin induction was recapitulated in an 
intraperitoneal animal model, though expression was not detected in tumors derived from 
subcutaneous heterotransplants. Additionally, putative bladder cancer stem cells did not 
express N-cadherin at high levels. These findings have broad implications in the field of 
biomarker and cancer research, in which the results of in vitro studies are not successful 
in clinical studies. By incorporating the factors of tumor microenvironment and cell 
population in the use of animal models, a greater number of cancer biomarkers and 
therapies may be successfully validated for clinical use.  
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Expression of N-cadherin Splice Variants 
 When all splice variants of N-cadherin mRNA were targeted, N-cadherin 
expression in UROtsa isolates As#5 and Cd#5 was not to the level of the bladder cancer 
cell lines J82 and TCCSUP, though expression was elevated compared with the RT4 cell 
line. The primers here are from Bio-Rad (qHsaCID00015189) and target splice variants 
ENST00000269141, ENST00000399380, ENST00000418492, ENST00000430882, and 
ENST00000413878. The splice variants detected by the Qiagen primers used for Figure 
3.23 only include NM_001792, XM_005258181, and XM_005258182. 
 
Figure 5.1 Expression of total N-cadherin splice variants in As
3+
- and Cd
2+
-
transformed UROtsa is lower than that of J82 and RT4 cell lines. RT-PCR analysis 
of N-cadherin expression in the highest N-cadherin-expressing transformed isolates and 
three human bladder cancer cell lines. Data expressed as fold change normalized to β-
actin. PCR results represent Mean ±SEM of triplicate determinations.
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P-cadherin Expression 
P-cadherin is typically expressed in low amounts at the basal cell layer of the 
urothelium with aberrant expression investigated as a bladder cancer biomarker. Further, 
the expression of P-cadherin has been recently proposed as a bladder cancer stem cell 
marker (Bryan, 2014). 
 
 
Figure 5.2 P-cadherin expression is variable in As
3+
- and Cd
2+
-transformed UROtsa 
cells. Real time RT-PCR analysis expressed as fold change over parent normalized to β-
actin in A) As
3+
 isolates and B) Cd
2+
 isolates. Results represent Mean ±SEM of triplicate 
determinations. *p<0.05, **p<0.01, ***p<0.001. 
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Eukaryotic Elongation Factor 1A2 Expression 
 
Eukaryotic elongation factor 1A2, or eEF1A2, is a subunit of the elongation factor 
1 complex that promotes translation elongation. eEF1A2 is a proto-oncogene, with 
overexpression observed in a number of cancers including prostate, ovarian, and colon 
cancer. Translation elongation factors have been associated with cadmium carcinogenesis 
(Joseph, 2009). Commercial antibodies for eEF1A2 are not specific and also target 
eEF1A2, though the Scaggiante group has developed specific antibodies (Scaggiante et 
al., 2012).  
 
Figure 5.3 eEF1A2 is induced in Cd
2+
 transformants in vitro. A) PCR array validation 
results for eukaryotic elongation factor 1A2 in Cd
2+
-transformed UROtsa cells. Isolate #1 
was not included in array. B) Real time RT-PCR analysis expressed as fold change over 
parent confirms significant induction, though trends among isolates differ from the initial 
PCR array. Annealing temperature was optimized to 66
o
. C) Western blot analysis for 
eEF1A2 protein in Cd
2+
-transformed UROtsa and parent cells. *Isolate #3 is SC 
heterotransplant protein. Results represent Mean ±SEM of triplicate determinations. 
*p<0.05, **p<0.01, ***p<0.001 
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Figure 5.4 eEF12 expression is dependent upon Cd
2+
 exposure in non-malignant 
UROtsa cells. Real time RT-PCR analysis of eEF1A2 in parent UROtsa cells and Cd
2+
-
exposed isolates in vitro. eEF1A2 mRNA is elevated following 48 hrs 1 µM Cd
2+
 
exposure to parent UROtsa cells. Induction was most apparent at 48 hrs. A) UROtsa cells 
exposed to 0, 1, 2, and 4 µM cadmium chloride for 12, 48, and 72 hrs expressed as fold 
change over time-matched non-treated control. B) Selected results from 1 µM exposure at 
all time points. Data represented as fold change over parent UROtsa cells at 0 hrs 
exposure. Results represent Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, 
***p<0.001 
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Figure 5.5 eEF1A2 expression is regulated by histone acetylation state. eEF1A2 
mRNA expression is induced in a dose-dependent manner following 24, 48, and 72 hr 
exposure to the histone deacetylase inhibitor MS-275 in parent UROtsa cells. UROtsa 
cells were only exposed to 10X MS-275 at the 24 hr time point. Expression increases 
with duration of exposure between 24 and 48 hrs, followed by a decrease at 72 hrs, while 
dose-dependent expression is maintained.  
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NR2F1 and NR2F2 Induction in As
3+
- and Cd
2+
-transformed UROtsa Cells 
 
 Nuclear receptor subfamily 2, group F, member 1 (NRF2F1) and member 2 
(NRF2F2) experiments were performed by undergraduate Andrew Millbridge. 
Previously, RT-PCR analysis of 39 transitional cell carcinomas demonstrated a 
significant decrease in NR2F1 expression relative to normal tissue from the same patients 
(Ham, Lee, Yu, & Choi, 2008). In the bladder cancer cell line J82, retinoic acid-induced 
growth inhibition and apoptosis is promoted by NR2F1 (B. Lin, Chen, Xiao, & Kumar, 
2000). NR2F1 and NR2F2 have almost completely identical DNA binding domains, 
though the N-terminal regions of the two proteins significantly differ (Tsai & Tsai, 1997). 
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Figure 5.6 NR2F1 is induced in As
3+
- and Cd
2+
-transformed isolates and 
corresponding subcutaneous heterotransplants. A) Real time RT-PCR analysis of 
NR2F1 in parent UROtsa cells and As
3+
 and Cd
2+
 isolates in vitro. B) Real time RT-PCR 
analysis of NR2F1 in parent UROtsa cells and As
3+
 and Cd
2+
 SC heterotransplants. C) 
NR2F1 expression with 0, 1, 2, and 4 µM Cd
2+
 exposure for 12, 24, 48, and 72 hrs. D) 
NR2F1 expression after 0, 1, 2, and 3 µM As
3+
 exposure for 12, 24, 48, and 72 hrs. Data 
expressed as fold change relative to parent UROtsa cell line. PCR results represent Mean 
±SEM of triplicate determinations. 
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Figure 5.7 NR2F2 remains mostly unchanged in As
3+
- and Cd
2+
-transformed isolates 
in vitro, but is reduced in subcutaneous tumors. Real time RT-PCR analysis of NR2F1 
in A) As
3+
 transformants and B) Cd
2+
 isolates in vitro. C) As
3+
 SC tumors and D) Cd
2+
 
SC tumors. E) Short-term As
3+
 exposure to parent UROtsa cells. F) Short-term Cd
2+
 
exposure to parent UROtsa cells. Data is expressed as fold change over parent. PCR 
results represent Mean ±SEM of triplicate determinations. 
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Microarray Validation by Short-term As
3+
 Exposure 
 To determine genes of interest from those differentially expressed in As
3+
-
transformed UROtsa, the top five-induced genes from the microarray were selected and 
changes in gene expression following short-term arsenic exposure were measured. The 
genes include UDP glycosyltransferase 8 (UGT8), latrophilin 2 (LPHN2), LIM and 
calponin homology domains 1 (LIMCH1), carboxypeptidase 6 (CPA6), and eukaryotic 
elongation factor 1 alpha 2 (eEF1A2). eEF1A2 was the only gene significantly altered by 
arsenic exposure, with results listed in a separate figure.  
 
Figure 5.8 Microarray validation by analysis of short-term As
3+
 exposure. Selected 
genes were the top-most induced on the As
3+
 array, and significantly increased on the 
array of Cd
2+
-transformed UROtsa cells. A) UGT8, B), LPHN2, C) LIMCH1, and D) 
CPA6 revealed no alteration in expression following one or three days with 6 µM sodium 
arsenite. Data is expressed as fold change over parent. PCR results represent Mean ±SEM 
of triplicate determinations. 
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Neurotrophin-3 Expression in As
3+
- and Cd
2+
-transformed UROtsa Cells 
Neurotrophin-3 (NTF3 or NT3) experiments were performed by undergraduate 
Tyler Titcomb. A review of scientific literature and omics signatures for muscl-invasive 
bladder cancer revealed that the neurotrophin signaling pathway was significantly 
associated with the disease (Bhat et al., 2015).  
 
Figure 5.9 NTF3 is reduced in As
3+
-transformed UROtsa cells at the mRNA and 
protein level. A) Real time RT-PCR for neurotrophin-3 in parent and As
3+
 transformants 
expressed as fold change over parent. PCR results represent Mean ±SEM of triplicate 
determinations. B) Western blot analysis for NTF3 at 35 kDa. 
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Figure 5.10 NTF3 is induced in Cd
2+
-transformed UROtsa cells. A) Real time RT-
PCR analysis for NTF3 expressed as fold change over parent. PCR results represent 
Mean ±SEM of triplicate determinations. B) Western blot analysis for NTF3 at 35 kDa. 
*p<0.05, **p<0.01, ***p<0.001 
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Figure 5.11 Neurotrophin-3 expression is increased in As
3+
 and Cd2
+ 
subcutaneous 
tumors. Real time RT-PCR analysis for NTF-3 in A) As
3+
 SC tumors and B) Cd
2+ 
SC 
tumors expressed as fold change over parent. PCR results represent Mean ±SEM of 
triplicate determinations. *p<0.05, **p<0.01, ***p<0.001 
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Figure 5.12 Neurotrophin-3 expression is unchanged following short-term As
3+
 and 
Cd
2+
 exposure. A) Real time RT-PCR for short-term sodium arsenite exposed parent 
UROtsa cells. The 48 hr time point samples were likely misquantified. B) RT-PCR 
analysis for short-term cadmium chloride exposure. Data expressed as fold change over 
parent. PCR results represent Mean ±SEM of triplicate determinations. *p<0.05, 
**p<0.01, ***p<0.001 
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Figure 5.13 Neurotrophin-3 expression is altered by histone deacetylase inhibitor 
and DNA methyltransferase inhibitor treatment. parent UROtsa cells were treated 
with MS-275 for 24 hrs and 5’-azacytidine for 48 hrs. Real time RT-PCR results 
expressed as fold change over parent. PCR results represent Mean ±SEM of triplicate 
determinations. *p<0.05, **p<0.01, ***p<0.001 
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Ephrin Receptor A4 Induction in As
3+
- and Cd
2+
-transformed UROtsa Cells 
Ephrin receptor A4 (EPHA4) research was performed by undergraduate Tyler 
Titcomb. EPHA4 promotes motility and invasion in pancreatic and prostate cancer 
(Batson, Maccarthy-Morrogh, Archer, Tanton, & Nobes, 2014; C. Liu, Huang, Wang, 
Kong, & Zhang, 2014) and is correlated with gastric cancer recurrence (Oki et al., 2008).  
 
Figure 5.14 Ephrin Receptor A4 expression is increased in As
3+
 and Cd
2+
 
transformants. Real time RT-PCR analysis in A) As
3+
-transformed and B) Cd
2+
-
transformed UROtsa cells expressed as fold change over parent. PCR results represent 
Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, ***p<0.001 
 
 
Figure 5.15 EPHA4 expression is elevated in As
3+ 
and Cd
2+
 subcutaneous tumors. 
Real time RT-PCR analysis of A) As
3+
 SC tumors and B) Cd
2+
 SC tumors expressed as 
fold change over parent. PCR results represent Mean ±SEM of triplicate determinations. 
*p<0.05, **p<0.01, ***p<0.001 
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Figure 5.16 EPHA4 expression is induced after 12 hrs As
3+
 exposure. A) Real time 
RT-PCR analysis of parent UROtsa cells exposed to sodium arsenite. B) RT-PCR 
analysis of short-term cadmium chloride. PCR results represent Mean ±SEM of triplicate 
determinations. 
 
 
Figure 5.17 EPHA4 is induced by MS-275, but not 5’-AZC treatment. Parent UROtsa 
cells treated with 24 hrs MS-275 and 48 hrs 5’-azacytidine. Real time RT-PCR analysis 
expressed as Mean ±SEM of triplicate determinations. 
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Ets Variant 7 Induction in As
3+
- and Cd
2+
-transformed UROtsa Cells 
Ets variant 7 (ETV7) is also known as telomere length regulation protein (Tel2). 
Experiments evaluating the expression of this gene were performed by undergraduate 
Andrew Millbridge. ETV7 functions as a protein to mediate Hsp90 regulation of 
phosphatidylinositol-3 kinase-like kinases (PIKKs), proteins involved in DNA repair, cell 
cycle control, regulation of cell growth, degradation of mRNA, and control of gene 
expression (Takai, Wang, Takai, Yang, & de Lange, 2007). Hsp90 activates PIKKs via 
the R2TP complex and ETV7, in which ETV7 mediates the interaction between PIKKs 
and the R2TP complex. ETV7 stabilizes PIKK enzymes including mTOR, SMG1, and 
ATM (Horejsí et al., 2010; Kaizuka et al., 2010). Further, ETV7 mediates the recruitment 
of ATM1/Tel1 kinase to the site of double stranded DNA breaks for repair (Anderson et 
al., 2008). ETV7 can also act as a transcription factor (Gu et al., 2001). Expression of 
ETV7 in cancers has been little studied. ETV7 expression is elevated in breast cancer (J. 
He et al., 2007) and is considered a hematopoietic oncogene (Carella et al., 2006), and 
increased ETV7 protein is observed in hepatocellular carcinoma (Matos, Witzmann, 
Cummings, & Schmidt, 2009).  However, ETV7 is reduced in drug-resistant gastric 
cancer (O. Maeda et al., 2014). 
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Figure 5.18 Ets variant 1 expression is induced in As
3+
 and Cd
2+ 
transformants. Real 
time RT-PCR analysis of ETV7 in A) As
3+
-transformed UROtsa cells and B) Cd
2+
-
transformed UROtsa cells expressed as fold change normalized to β-actin. PCR results 
represent Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, ***p<0.001 
 
 
Figure 5.19 ETV7 is reduced in As
3+
 subcutaneous tumors, and relatively 
unchanged in Cd
2+
 tumors. Real time RT-PCR analysis of ETV7 in A) As
3+
 SC tumors 
and B) Cd
2+
 SC tumors expressed as fold change normalized to β-actin. PCR results 
represent Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, ***p<0.001
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ITM2C Expression 
Experiments on integral membrane protein 2c (ITM2C) expression were 
performed by undergraduate Andrew Millbridge. ITM2C expressed highly in the brain 
and is an inhibitor of beta-amyloid peptide production, but is known about the function of 
ITM2C outside the brain. 
 
Figure 5.20 ITM2C expression is varied in As
3+
 and Cd
2+
 transformants in vitro, 
though reduced in subcutaneous tumors. Real time RT-PCR analysis of ITM2C in A) 
As
3+
-transformed UROtsa cells, B) Cd
2+
-transformed UROtsa cells, C) As
3+
 SC tumors, 
and D) Cd
2+
 SC tumors expressed as fold change normalized to 18S. PCR results 
represent Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, ***p<0.001
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ABBREVIATIONS 
67LR 67-kDa laminin receptor 
8-oxo-dGTP 8-oxo-7,8-dihydrodeoxyguanosine triphosphate 
ABC transporter ATP-binding cassette transporter 
ALDH1A1 aldehyde dehydrogenase 1 family, member A1 
ANOVA one-way analysis of variance  
AP-1 activator protein 1 
Ape-1 apurinic/apyrimidinic endonuclease 1 
As
3+
 arsenite 
ATSDR Agency for Toxic Substances and Disease Registry 
5’-AZC 5’-azacytidine 
Bmi-1 B cell-specific Moloney murine leukemia virus integration site 1  
BSA bovine serum albumin 
Cd
2+
 cadmium 
CdCl2 cadmium chloride 
ChIP chromatin immunoprecipitation 
CK20 keratin 20 
CO2 carbon dioxide 
CTBP1 c-terminal binding protein 1  
DAB 3,3’-diaminobenzidine 
DAPK death-associated protein kinase 
DMA(III) dimethylarsinous acid  
DMA(V) dimethylarsinic acid 
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DMEM Dulbecco’s Modified Eagle Medium 
DMT1 divalent metal transporter 1 
DNA deoxynucleic acid 
E-cadherin epithelial-cadherin 
ECL electrochemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
eEF1A2 eukaryotic translation elongation factor 1 alpha 2  
EGF epidermal growth factor 
EMT epithelial-mesenchymal transition 
EPA Environmental Protection Agency 
EPHA4 ephrin receptor A4 
ERK extracellular signal-related kinase 
ETV7 ets variant 7 
FDA Food and Drug Administration 
GATA-4 GATA-binding factor 4 
H3K9Me3 histone 3 lysine 9 trimethylation 
H4Ac histone 4 acetylation 
HDACi histone deacetylase inhibitor 
HIF-2α hypoxia-inducible factor 2 alpha 
HRP horseradish peroxidase 
hrs hours 
Hsp heat shock protein 
IARC International Agency for Research on Cancer 
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IHC immunohistochemistry 
IL1RN interleukin 1 receptor antagonist 
IP intraperitoneal 
ITM2C integral membrane protein 2c 
Jak Janus family tyrosine kinase LAS-AF 
LCN2 lipocalin-2 
MAPK mitogen-activated protein kinase 
MDR1 multi-drug resistance  
µl microliter 
µM micromolar 
min minute 
miRNA microRNA 
MMA(III) monomethylarsonous acid  
MMA(V) monomethylarsonic acid 
MMP9 matrix metallopeptidase 9   
mRNA messenger RNA 
MSH Mut S homolog  
MZF1 myeloid zinc finger 1 
NaAsO2 sodium arsenite 
N-cadherin neuronal-cadherin 
NFĸB2 nuclear factor ĸ B 
NR2F1 nuclear receptor subfamily 2, group f, member 1 
NR2F2 nuclear receptor subfamily 2, group f, member 2 
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NRF2 nuclear factor (erythroid-derived 2)-like 2 
NTF3 neurotrophin-3 
NTP National Toxicology Program 
OCLN occludin 
Oct-4 octamer-binding transcription factor 4 
PBS phosphate-buffered saline 
P-cadherin placenta-cadherin 
PE phycoerythrin 
PMSF phenylmethanesulfonylfluoride 
PVDF polyvinylidene difluoride 
RBPJ recombination signal binding protein for immunoglobulin kappa J   
 region 
 
RECK reversion-inducing-cysteine-rich protein with kazal motifs 
RNA ribonucleic acid 
ROS reactive oxygen species 
RT-PCR real-time polymerase chain reaction    
SEM standard error of the mean 
S100P S100 calcium binding protein P 
SC subcutaneous 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis  
siRNA small interfering RNA 
SLC1A2 solute carrier family 1 (glial high affinity glutamate transporter),  
 member 2 
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SLC39A14 solute carrier family 39 (zinc transporter), member 14 
SMAD4 SMAD family member 4 
Sox2 SRY (sex-determining region Y)-box 2 
Sox9 SRY (sex-determining region Y)-box 9 
SPARC secreted protein, acidic, cysteine-rich 
STAT signal transducer and activator of transcription 
STEAP1 six transmembrane epithelial antigen of the prostate 1 
TCF4 transcription factor 4 
TGF-β transforming growth factor beta 
Tris-HCl Tris-hydrochloride 
VEGFR vascular endothelial growth factor receptor 
XPA xeroderma pigmentosum, complementation group A 
XRCC3 X-ray repair complementing defective repair in Chinese hamster  
 cells 3 
 
YB-1 Y-box binding protein 1 
ZIP14 zrt- and irt-like protein 
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